


40 Rec'd PCT/PTO 0 2 OCT 2000

FORM-PTO-1390 (Rev. 12-29-99)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER
<b>TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371</b>			031309-003
			U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.5) <b>09/647543</b>
INTERNATIONAL APPLICATION NO. PCT/EP99/02243	INTERNATIONAL FILING DATE 1 April 1999	PRIORITY DATE CLAIMED 2 April 1998	
TITLE OF INVENTION <b>PROMOTER AND CONSTRUCTIONS FOR EXPRESSION OF RECOMBINANT PROTEINS IN FILAMENTOUS FUNGI</b>			
APPLICANT(S) FOR DO/EO/US <b>Heidi Sisniega BARROSO et al.</b>			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.			
2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.			
3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than at the expiration of the applicable time limit set in 35 U.S.C. 371(b) and the PCT Articles 22 and 39(1).			
4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.			
5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))			
a. <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).			
b. <input type="checkbox"/> has been transmitted by the International Bureau.			
c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US)			
6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).			
7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))			
a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).			
b. <input type="checkbox"/> have been transmitted by the International Bureau.			
c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.			
d. <input checked="" type="checkbox"/> have not been made and will not be made.			
8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).			
9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).			
10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).			
<b>Items 11. to 16. below concern other document(s) or information included:</b>			
11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.			
12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.			
13. <input checked="" type="checkbox"/> A FIRST preliminary amendment.			
<input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.			
14. <input type="checkbox"/> A substitute specification.			
15. <input type="checkbox"/> A change of power of attorney and/or address letter.			
16. <input checked="" type="checkbox"/> Other items or information: Sequence Listing in computer readable form and a paper copy.			



U.S. APPLICATION NO. (If known) <b>097/647543</b> Unassigned	INTERNATIONAL APPLICATION NO. PCT/EP99/02243	ATTORNEY'S DOCKET NUMBER 031309-003
---	---	--

17. <input checked="" type="checkbox"/> The following fees are submitted:	<b>CALCULATIONS</b>	PTO USE ONLY
<b>Basic National Fee (37 CFR 1.492(a)(1)-(5)):</b>  Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO ..... \$1,000.00 (960)  International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... \$860.00 (970)  International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... \$710.00 (958)  International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... \$690.00 (956)  International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) ..... \$100.00 (962)		
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>	<b>\$ 860.00</b>	
Surcharge of <b>\$130.00 (154)</b> for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)). <div style="float: right;">           20 <input type="checkbox"/> 30 <input type="checkbox"/> </div>		
Claims	Number Filed	Number Extra
Total Claims	61 -20 =	41
Independent Claims	9 -3 =	6
Multiple dependent claim(s) (if applicable)		+ \$270.00 (968)
<b>TOTAL OF ABOVE CALCULATIONS =</b>		<b>\$ 2,078.00</b>
Reduction for 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.8, 1.27, 1.28).		
<b>SUBTOTAL =</b>		<b>\$ 2,078.00</b>
Processing fee of <b>\$130.00 (156)</b> for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492(f)). <div style="float: right;">           20 <input type="checkbox"/> 30 <input type="checkbox"/> </div>		
<b>TOTAL NATIONAL FEE =</b>		<b>\$ 2,078.00</b>
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). <b>\$40.00 (581)</b> per property +		
<b>TOTAL FEES ENCLOSED =</b>		<b>\$ 2,078.00</b>
		Amount to be:
		refunded \$
		charged \$

a. ☒ A check in the amount of \$ 2,078.00 to cover the above fees is enclosed.


b. ☐ Please charge my Deposit Account No. 02-4800 in the amount of \$ \_\_\_\_\_ to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 02-4800. A duplicate copy of this sheet is enclosed.

**NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.**

SEND ALL CORRESPONDENCE TO:

Patrick C. Keane  
 BURNS, DOANE, SWECKER & MATHIS, L.L.P.  
 P.O. Box 1404  
 Alexandria, Virginia 22313-1404  
 (703) 836-6620

  
 SIGNATURE  
 Patrick C. Keane  
 NAME  
32,858  
 REGISTRATION NUMBER

Patent  
Attorney's Docket No. 031309-003

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of )  
Heidi Sisniega BARROSO et al. ) Group Art Unit: Unassigned  
Application No.: Unassigned ) Examiner: Unassigned  
Filed: )  
For: PROMOTER AND )  
CONSTRUCTIONS FOR )  
EXPRESSION OF RECOMBINANT )  
PROTEINS IN FILAMENTOUS )  
FUNGI )

**PRELIMINARY AMENDMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Prior to an examination on the merits, please amend the above identified application  
as follows:

**IN THE SPECIFICATION:**

On substitute sheet 2A, line 1, delete "Gene (1983) ," and insert therefor --Gene  
(1983),--;

line 2, delete "Neurospora crassa" and insert therefor --Neurospora  
crassa--;

line 3, delete "Appl. Microbiol. Biotechnol. (1997), Vol." and insert  
therefor --Appl. Microbiol. Biotechnol. (1997), vol.--

On page 3, lines 4 and 9, delete both instances of "SEQ ID No. 1" and insert therefor --SEQ ID NO:1--.

On page 3, line 7, change "Aspergillus nidulans" to --Aspergillus nidulans--

On page 3, line 18, delete "SEQ ID No. 1" and insert therefor --SEQ ID NO:1--;

On page 4, lines 1, 4, 12 and 18, delete all instances of "SEQ ID No. 1" and insert therefor --SEQ ID NO:1--;

line 33, delete "SEQ ID No. 2" and insert therefor --SEQ ID NO:2--.

On page 4, line 15, change "Aspergillus nidulans" to --Aspergillus nidulans--

On page 6, line 27, delete "SEQ ID No. 1" and insert therefor --SEQ ID NO:1--.

On page 8, line 7, delete "SEQ ID No. 1" and insert therefor --SEQ ID NO:1--.

On page 12, line 13, delete "Genebank" and insert therefor --Genbank--.

On page 20, lines 19 and 22, delete both instances of "SEQ ID No. 1" and insert therefor --SEQ ID NO:1--.

On page 21, line 14, delete "SEQ ID No. 2" and insert therefor --SEQ ID NO:2--.

On page 22, line 1, delete "A. nidulans" and insert therefor --A. nidulans--.

On page 24, line 14, delete "SEQ ID No. 1" and insert therefor --SEQ ID NO:1--.

On page 28, line 22, delete "paralell" and insert therefor --parallel--.

002001-24527966

On page 35, line 16, delete "Cat.No." and insert therefor -Cat. No.-.

**IN THE CLAIMS:**

Please note that the claims on amended pages 1-5 attached to the International Preliminary Examination Report (Annexes) and submitted herewith, have replaced the originally filed pages 48-52 of the application. The claims to be examined and amended by this preliminary amendment are found on amended pages 1-5.

Please cancel claims 16, 17 and 35 without prejudice or disclaimer as to the subject matter contained therein.

Please amend the claims of amended pages 1-5 as follows:

1. (Amended) An isolated nucleic acid comprising a [A] promoter for the expression of recombinant proteins in filamentous fungi that comprises a nucleotide sequence [-] or a complementary strand thereof [-] selected from the group consisting of: (a) nucleotides [the nucleotide sequence numbered] 1-740 of [in the enclosed SEQ ID No. 1] SEQ ID NO:1; and (b) a nucleotide sequence that hybridizes under stringent conditions to that defined in (a), with the proviso, that the nucleotide sequence is not the promoter of the [gdh] gdh gene [for] from *Aspergillus nidulans* [*Aspergillus nidulans*].

2. (Amended) An isolated nucleic acid [A promoter] according to claim 1, wherein the promoter [which has] consists of [the sequence of] nucleotides [numbered] 1-740 [in SEQ ID No. 1] of SEQ ID NO:1 or its complementary strand.

3. (Amended) An isolated nucleic acid comprising a [Isolated] promoter of a glutamate dehydrogenase gene from a fungus of the genus *Aspergillus* [*Aspergillus*] with

002001-44574960

the proviso[,] that the sequence is not the promoter of the *gdh* [*gdh*] gene from *Aspergillus nidulans* [*Aspergillus nidulans*].

4. (Amended) The isolated nucleic acid [Isolated promoter] according to claim 3, wherein the fungus is *Aspergillus awamori* or *Aspergillus niger* [*Aspergillus awamori* or *Aspergillus niger*].

5. (Amended) The isolated nucleic acid [Isolated promoter] according to claim 4, wherein the fungus is *Aspergillus awamori* [*Aspergillus awamori*].

6. (Amended) A purified and isolated DNA sequence that encodes a glutamate dehydrogenase protein and that comprises a nucleotide sequence [-] or a complementary strand thereof [-] selected from the group consisting of: (a) nucleotides [the nucleotide sequence numbered] 741-2245 [in the enclosed SEQ ID No. 1] of SEQ ID NO:1; and (b) a nucleotide sequence that hybridizes under stringent conditions to that defined in (a), with the proviso[,] that the sequence is not the [*gdh*] *gdh* gene from *Aspergillus nidulans* [*Aspergillus nidulans*].

7. (Amended) [A] The DNA sequence according to claim 6, [which has the sequence of] consisting of nucleotides [numbered 741-2242 in SEQ ID No. 1] 741-2245 of SEQ ID NO:1, or its complementary strand.

8. (Amended) An isolated DNA sequence encoding a glutamate dehydrogenase from a fungus of the genus *Aspergillus*, [*Aspergillus*,] with the proviso[,] that the sequence is not the [*gdh*] *gdh* gene from *Aspergillus nidulans* [*Aspergillus nidulans*].

9. (Amended) The [An] isolated DNA sequence according to claim 8, wherein the fungus is *Aspergillus awamori* or *Aspergillus niger* [*Aspergillus awamori* or *Aspergillus niger*].

002001-3454960

10. (Amended) The [An] isolated DNA sequence according to claim 9, wherein the fungus is *Aspergillus awamori* [Aspergillus awamori].

11. (Amended) A [The] protein encoded by any of the DNA sequences according to claim 6.

12. (Amended) A [The] protein [which has the amino acid sequence is SEQ ID No. 2] comprising SEQ ID NO:2.

13. (Amended) An isolated glutamate dehydrogenase from a fungus of the genus *Aspergillus* [Aspergillus] with the proviso[,] that the glutamate dehydrogenase is not the glutamate dehydrogenase from *Aspergillus nidulans* [Aspergillus nidulans].

14. (Amended) The [An] isolated glutamate dehydrogenase according to claim 13, wherein the fungus is *Aspergillus awamori* or *Aspergillus niger* [Aspergillus awamori or Aspergillus niger].

15. (Amended) The [An] isolated glutamate dehydrogenase according to claim 14, wherein the fungus is *Aspergillus awamori* [Aspergillus awamori].

18. (Amended) A DNA [construction] construct [that comprises] comprising: a) a promoter from a glutamate dehydrogenase gene from a fungus of the genus *Aspergillus* [Aspergillus]; b) a DNA sequence encoding a protein [normally] expressed from a filamentous fungus or a portion thereof; c) a DNA sequence encoding a cleavable linker peptide; and d) a DNA sequence encoding a desired protein.

19. (Amended) A DNA [construction] construct that comprises: a) a promoter from a glutamate dehydrogenase gene from a fungus of the genus *Aspergillus*; b) a DNA sequence encoding a protein expressed from a filamentous fungus or a portion thereof; c) a

002001-24547960

DNA sequence encoding a cleavable linker peptide; and d) a DNA sequence encoding a desired protein [according to claim 18], wherein the promoter under a) is a promoter according to claim 1 [any one of claims 1 to 5].

20. (Amended) The [A] DNA [construction] construct according to claim 18, wherein the DNA sequence under b) encodes a protein or portion thereof selected from the group consisting of: i) glucoamylase from *Aspergillus awamori*, *Aspergillus niger*, *Aspergillus oryzae* or *Aspergillus sojae* [*Aspergillus awamori*, *Aspergillus niger*, *Aspergillus oryzae* or *Aspergillus sojae*]; ii) B2 from *Acremonium chrysogenum* [*Acremonium chrysogenum*]; and iii) a glutamate dehydrogenase from a filamentous fungus.

21. (Amended) The [A] DNA [construction] construct according to claim 20, wherein the DNA sequence under b) encodes a glucoamylase from *Aspergillus awamori*, *Aspergillus niger*, *Aspergillus oryzae* or *Aspergillus sojae* [*Aspergillus awamori*, *Aspergillus niger*, *Aspergillus oryzae* or *Aspergillus sojae*] or a portion thereof.

22. (Amended) The [A] DNA [construction] construct according to claim 20, wherein the DNA sequence under b) encodes [the] protein B2 from *Acremonium chrysogenum* [*Acremonium chrysogenum*] or a portion thereof.

23. (Amended) The [A] DNA [construction] construct according to claim 20, wherein the DNA sequence under b) encodes a glutamate dehydrogenase from a filamentous fungus or a portion thereof.

24. (Amended) The [A] DNA [construction] construct according to claim 18, wherein the DNA sequence under c) contains a KEX2 processing sequence.

09647543-100200



25. (Amended) The [A] DNA [construction] construct according to claim 18 [any one of claims 18 to 24], wherein the DNA sequence under d) encodes thaumatin.

26. (Amended) The [A] DNA [construction] construct according to claim 25, wherein the DNA sequence under d) is the thaumatin II synthetic gene from plasmid pThIX [disclosed in EP 684312].

27. (Amended) A DNA [construction] construct comprising a gdh promoter from a fungus of the genus *Aspergillus* [Aspergillus] operatively linked to a DNA sequence encoding a [recombinant] desired protein.

28. (Amended) A DNA [construction] construct comprising a gdh promoter from a fungus of the genus *Aspergillus* operatively linked to a DNA sequence encoding a desired protein [according to claim 27], wherein the promoter is a promoter according to claim 1 [any one of claims 1 to 5].

29. (Amended) A filamentous fungus culture capable of producing a recombinant protein which has been transformed with a plasmid containing a DNA construct [construction] according to claim 18 [any one of claims 18 to 28].

30. (Amended) The [A] culture according to claim 29, wherein the filamentous fungus is a fungus from the genus *Aspergillus* [Aspergillus].

31. (Amended) The [A] culture according to claim 29, wherein the filamentous fungus is selected from the group consisting of *Aspergillus awamori*, *Aspergillus niger*, *Aspergillus oryzae*, *Aspergillus nidulans* and *Aspergillus sojae* [Aspergillus awamori, Aspergillus niger, Aspergillus oryzae, Aspergillus nidulans and Aspergillus sojae].

09647543.100200

32. (Amended) A filamentous fungus culture capable of producing a recombinant protein which has been transformed with a plasmid [according to claim 29], wherein the plasmid contains a DNA [construction] construct according to claim 25 [any one of claims 25 or 26].

33. (Amended) A process for producing a recombinant protein in a filamentous fungus comprising [the following steps]:

- a) preparing [preparation of] an expression plasmid containing a DNA construct according to claim 18 [any of claims 18 to 28];
- b) transforming [transformation of] a strain of filamentous fungus with said expression plasmid;
- c) culturing [culture of] the transformed strain under appropriate nutrient conditions to produce the desired protein, either intracellularly, extracellularly or in both ways simultaneously; and
- d) separating and purifying [depending on the case, separation and purification of] the desired protein from the fermentation broth to produce the recombinant protein.

34. (Amended) The [A] process according to claim 33, wherein the recombinant protein is thaumatin and the expression plasmid contains a DNA construct [construction] according to claim 25 [claims 25 or 26].

Please add the following new claims:

--36. A method for expressing a recombinant protein in filamentous fungi comprising:

- (a) preparing a nucleic acid comprising a promoter from a glutamate dehydrogenase gene from a fungus of the genus *Aspergillus* operably linked to a second nucleic acid encoding a protein;

09647543-100200

- (b) inserting said nucleic acid into a filamentous fungi; and
- (c) culturing the filamentous fungi to express the recombinant protein.

37. The method of Claim 36, wherein the promoter is selected from the group consisting of:

- (a) nucleotides 1-740 of SEQ ID NO:1;
- (b) a nucleotide sequence that hybridizes under stringent conditions to nucleotides 1-740 of SEQ ID NO:1;
- (c) a promoter of a glutamate dehydrogenase gene from a fungus of the genus *Aspergillus* with the proviso that the sequence is not the promoter of the *gdh* gene from *Aspergillus nidulans*; and
- (d) a promoter of a glutamate dehydrogenase gene of *Aspergillus awamori* or *Aspergillus niger*.

38. A method of isolating a glutamate dehydrogenase gene comprising hybridizing a nucleotide sequence according to claim 1 to a nucleic acid under stringent conditions.

39. A filamentous fungus culture capable of producing a recombinant protein which has been transformed with a plasmid containing a DNA construct according to claim 19.

40. A filamentous fungus culture capable of producing a recombinant protein which has been transformed with a plasmid containing a DNA construct according to claim 20.

41. A filamentous fungus culture capable of producing a recombinant protein which has been transformed with a plasmid containing a DNA construct according to claim 21.

42. A filamentous fungus culture capable of producing a recombinant protein which has been transformed with a plasmid containing a DNA construct according to claim 22.

002001-24274960

43. A filamentous fungus culture capable of producing a recombinant protein which has been transformed with a plasmid containing a DNA construct according to claim 23.

44. A filamentous fungus culture capable of producing a recombinant protein which has been transformed with a plasmid containing a DNA construct according to claim 24.

45. A filamentous fungus culture capable of producing a recombinant protein which has been transformed with a plasmid containing a DNA construct according to claim 25.

46. A filamentous fungus culture capable of producing a recombinant protein which has been transformed with a plasmid containing a DNA construct according to claim 26.

47. A filamentous fungus culture capable of producing a recombinant protein which has been transformed with a plasmid containing a DNA construct according to claim 27.

48. A filamentous fungus culture capable of producing a recombinant protein which has been transformed with a plasmid containing a DNA construct according to claim 28.

49. A process for producing a recombinant protein in a filamentous fungus comprising:

- a) preparing an expression plasmid containing a DNA construct according to claim 19;
- b) transforming a strain of filamentous fungus with said expression plasmid;
- c) culturing the transformed strain under appropriate nutrient conditions to produce the desired protein, either intracellularly, extracellularly or in both ways simultaneously; and

002001-64574960

d) separating and purifying the desired protein from the fermentation broth to produce the recombinant protein.

50. A process for producing a recombinant protein in a filamentous fungus comprising:

- a) preparing an expression plasmid containing a DNA construct according to claim 20;
- b) transforming a strain of filamentous fungus with said expression plasmid;
- c) culturing the transformed strain under appropriate nutrient conditions to produce the desired protein, either intracellularly, extracellularly or in both ways simultaneously; and
- d) separating and purifying the desired protein from the fermentation broth to produce the recombinant protein.

51. A process for producing a recombinant protein in a filamentous fungus comprising:

- a) preparing an expression plasmid containing a DNA construct according to claim 21;
- b) transforming a strain of filamentous fungus with said expression plasmid;
- c) culturing the transformed strain under appropriate nutrient conditions to produce the desired protein, either intracellularly, extracellularly or in both ways simultaneously; and
- d) separating and purifying the desired protein from the fermentation broth to produce the recombinant protein.

52. A process for producing a recombinant protein in a filamentous fungus comprising:

- a) preparing an expression plasmid containing a DNA construct according to claim 22;

09647543.100200

- b) transforming a strain of filamentous fungus with said expression plasmid;
- c) culturing the transformed strain under appropriate nutrient conditions to produce the desired protein, either intracellularly, extracellularly or in both ways simultaneously; and
- d) separating and purifying the desired protein from the fermentation broth to produce the recombinant protein.

53. A process for producing a recombinant protein in a filamentous fungus comprising:

- a) preparing an expression plasmid containing a DNA construct according to claim 23;
- b) transforming a strain of filamentous fungus with said expression plasmid;
- c) culturing the transformed strain under appropriate nutrient conditions to produce the desired protein, either intracellularly, extracellularly or in both ways simultaneously; and
- d) separating and purifying the desired protein from the fermentation broth to produce the recombinant protein.

54. A process for producing a recombinant protein in a filamentous fungus comprising:

- a) preparing an expression plasmid containing a DNA construct according to claim 24;
- b) transforming a strain of filamentous fungus with said expression plasmid;
- c) culturing the transformed strain under appropriate nutrient conditions to produce the desired protein, either intracellularly, extracellularly or in both ways simultaneously; and
- d) separating and purifying the desired protein from the fermentation broth to produce the recombinant protein.

09647543.100200

55. A process for producing a recombinant protein in a filamentous fungus comprising:

- a) preparing an expression plasmid containing a DNA construct according to claim 25;
- b) transforming a strain of filamentous fungus with said expression plasmid;
- c) culturing the transformed strain under appropriate nutrient conditions to produce the desired protein, either intracellularly, extracellularly or in both ways simultaneously; and
- d) separating and purifying the desired protein from the fermentation broth to produce the recombinant protein.

56. A process for producing a recombinant protein in a filamentous fungus comprising:

- a) preparing an expression plasmid containing a DNA construct according to claim 26;
- b) transforming a strain of filamentous fungus with said expression plasmid;
- c) culturing the transformed strain under appropriate nutrient conditions to produce the desired protein, either intracellularly, extracellularly or in both ways simultaneously; and
- d) separating and purifying the desired protein from the fermentation broth to produce the recombinant protein.

57. A process for producing a recombinant protein in a filamentous fungus comprising:

- a) preparing an expression plasmid containing a DNA construct according to claim 27;
- b) transforming a strain of filamentous fungus with said expression plasmid;

002001.545496

c) culturing the transformed strain under appropriate nutrient conditions to produce the desired protein, either intracellularly, extracellularly or in both ways simultaneously; and

d) separating and purifying the desired protein from the fermentation broth to produce the recombinant protein.

58. A process for producing a recombinant protein in a filamentous fungus comprising:

a) preparing an expression plasmid containing a DNA construct according to claim 28;

b) transforming a strain of filamentous fungus with said expression plasmid;

c) culturing the transformed strain under appropriate nutrient conditions to produce the desired protein, either intracellularly, extracellularly or in both ways simultaneously; and

d) separating and purifying the desired protein from the fermentation broth to produce the recombinant protein.

59. A DNA construct that comprises: a) a promoter from a glutamate dehydrogenase gene from a fungus of the genus *Aspergillus*; b) a DNA sequence encoding a protein expressed from a filamentous fungus or a portion thereof; c) a DNA sequence encoding a cleavable linker peptide; and d) a DNA sequence encoding a desired protein, wherein the promoter under a) is a promoter according to claim 3.

60. A filamentous fungus culture capable of producing a recombinant protein which has been transformed with a plasmid containing a DNA construct according to claim 59.

61. A process for producing a recombinant protein in a filamentous fungus comprising:

09647543.100200



- a) preparing an expression plasmid containing a DNA construct according to claim 59;
- b) transforming a strain of filamentous fungus with said expression plasmid;
- c) culturing the transformed strain under appropriate nutrient conditions to produce the desired protein, either intracellularly, extracellularly or in both ways simultaneously; and
- d) separating and purifying the desired protein from the fermentation broth to produce the recombinant protein.

62. A DNA construct comprising a *gdh* promoter from a fungus of the genus *Aspergillus* operatively linked to a DNA sequence encoding a desired protein, wherein the promoter is a promoter according to claim 3.

63. A filamentous fungus culture capable of producing a recombinant protein which has been transformed with a plasmid containing a DNA construct according to claim 62.

64. A process for producing a recombinant protein in a filamentous fungus comprising:

- a) preparing an expression plasmid containing a DNA construct according to claim 62;
- b) transforming a strain of filamentous fungus with said expression plasmid;
- c) culturing the transformed strain under appropriate nutrient conditions to produce the desired protein, either intracellularly, extracellularly or in both ways simultaneously; and
- d) separating and purifying the desired protein from the fermentation broth to produce the recombinant protein.--

031309-003-10200

**REMARKS**

The Examiner's attention is drawn to the amendments to the application made in the Preliminary Examination Report, and for the convenience of the Examiner the following items are submitted with this application:

- A) International PCT Publication
- B) Preliminary Examination Report
- C) Substitute Sheets

The amendments to the specification corrects typographical errors and does not introduce any prohibited new matter.

Claims 1-15 and 18-34 have been amended to more distinctly claim the subject matter of the invention and place the claims in proper form in accordance with U.S. Patent Office procedures.

New claims 36-38 replace claims 16-17 and 35 respectively. Support for the new claims can be found, at least, in the claims as originally filed. No prohibited new matter is introduced by the amendment to the claims or by entry of the new claims.

New claims 39-48 replace the multiple dependencies of claim 29, and new claims 49-58 replace the multiple dependencies of claim 33. New claims 59-61 replace the multiple dependencies of claims 19, 29 and 33, respectively. New claims 62-64 replace the multiple dependencies of claims 28, 29 and 33, respectively.

Also, Applicants have amended the application to substitute the originally filed claim pages 48-52 with the amended claim pages 1-5 attached to the International Preliminary Examiner Report (Annexes) and included in the application as filed herewith.

Applicants retain the right to reintroduce any subject matter canceled by the present Amendment at any time during the prosecution of this application or any continuation or divisional thereof in the United States. It is believed that no prohibited new matter is being introduced by entry of this paper.

In view of the foregoing, an action on the merits is now believed to be in order. Such action is earnestly solicited.


09647543.100200

In the event that there are any questions relating to this application, it would be appreciated if the Examiner would telephone the undersigned attorney concerning such questions so that prosecution of this application may be expedited.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By:  Reg. No. 32,958

 Mercedes K. Meyer  
Registration No. 44,939

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620

Date: October 2, 2000

002001-24524960

09/647543

Promoter and constructions for expression of recombinant proteins in filamentous fungi

5 This invention relates to improvements in the expression of proteins, particularly of fusion proteins, by recombinant DNA technology, using filamentous fungi as the host. These improvements refer mainly to the use of a new promoter and new DNA constructions containing it.

10 DESCRIPTION OF THE PRIOR ART

Filamentous fungi are known to produce in nature a wide range of homologous proteins in large amounts. For this reason, filamentous fungi have been regarded as attractive hosts for  
15 the expression of recombinant proteins. For instance, Aspergillus awamori has been used for the production of recombinant proteins such as bovine chymosin and human lactoferrin.

20 Some recombinant proteins, however, have proved to be very difficult to express in filamentous fungi. This is the case for example of interleukin-6 and thaumatin. The thaumatins are proteins with a very sweet taste and the ability to increase the palatability of food. In industry they are currently  
25 extracted from the arils of the fruit of the plant Thaumatococcus daniellii Benth (M.Witty, J.D. Higginbotham, Thaumatin, 1994, CRC Press, Boca Ratón, Florida). Thaumatin can be isolated from these arils in at least five different forms (I, II, III, b and c), thaumatins I and II being the  
30 most abundant types in the arils. Despite its advantages, industrial use of thaumatins of plant origin is very limited because of the extreme difficulty involved in obtaining the fruit from which it is extracted. Attempts have been made to produce thaumatins by genetic engineering in different hosts  
35 such as bacteria, yeasts and transgenic plants, but until now the results have been considered disheartening and thus the thaumatin available to industry is very scarce and expensive.

ART 34 AMDT

14.05.05.00

2

European patent EP 684312 describes a process for preparing recombinant thaumatin in filamentous fungi. One problem of this process is that the yields obtained are low in comparison with those needed for industrial production of thaumatins.

5

It is known in the art that yields of recombinant proteins can be improved when the recombinant protein of interest is expressed as a fusion with another protein, and when expression of this cassette is driven by a strong fungal promoter. This other protein, named "carrier protein", is usually a highly expressed protein of fungal origin. Up to now, the most frequently used expression system involves the glucoamylase promoter and gene from Aspergillus awamori as the promoter and the carrier protein, respectively (P.P. Ward et al., Biotechnology 1995, vol. 13, pp. 498-502). However, in some cases the use of this expression system does not lead to high levels of the desired recombinant protein. One of these specially problematic cases is the expression of recombinant thaumatin in filamentous fungi.

→ Insert page 2a ←

In view of the above, it is clear that there is the need to provide new and more efficient expression systems that allow the production of higher concentrations of those proteins that are difficult to express in filamentous fungi, such as thaumatins. This goal is achieved with the new promoter and DNA constructions provided in the present invention, as explained below.

#### DESCRIPTION OF THE INVENTION

30

The present invention provides a new expression system that makes use of the promoter from the glutamate dehydrogenase (gdh) gene from filamentous fungi of the genus Aspergillus, particularly from Aspergillus awamori.

35

One of the objects of the present invention is a new promoter for the expression of recombinant proteins in

11.05.00.00

Page 2a

Insertion for page 2

Gene (1983) , vol. 26, pp. 253-260 discloses the complete nucleotide sequence of the *Neurospora crassa* NADP-specific glutamate dehydrogenase gene.

Appl. Microbiol. Biotechnol. (1997), Vol. 47, pp 1-11 discloses the efficient production of secreted proteins by *Aspergillus*. Particular focus is laid on the gene fusion strategies.

EP 0 684 312 A2 relates to a preparation process of a natural protein sweetener, thaumatin. Said document discloses a new nucleotide sequence encoding thaumatin with optimised codon usage for expression in filamentous fungi.

002007-4152490

05.05.00

filamentous fungi that comprises a nucleotide sequence - or a complementary strand thereof - selected from the group consisting of: (a) the nucleotide sequence numbered 1-740 in the enclosed SEQ ID No. 1; and (b) a nucleotide sequence that hybridizes under stringent conditions to that defined in (a) with the proviso that the sequence is not the promoter of the *gdh* gene from *Aspergillus nidulans*. Particularly preferred is the promoter comprising the sequence defined in (a), i.e. the nucleotide sequence numbered as 1-740 in SEQ ID No. 1, which corresponds to the *gdhA* promoter of the glutamate dehydrogenase A gene from *Aspergillus awamori*.

Although glutamate dehydrogenase A disclosed herein is the first glutamate dehydrogenase identified and described in the filamentous fungus *Aspergillus awamori*, there may exist other glutamate dehydrogenases in *Aspergillus awamori*. The novel nucleotide sequence of the *Aspergillus awamori* *gdhA* promoter and/or gene shown in SEQ ID No. 1 or a portion thereof can be used as a probe for the identification and isolation of other homologous promoters/genes of glutamate dehydrogenases in *Aspergillus awamori* as well as in other organisms, preferably in filamentous fungi, more preferably in fungi of the genus *Aspergillus*, still more preferably in *Aspergillus awamori* and *Aspergillus niger*, and specially in *Aspergillus awamori*, following the teachings of the present invention. Consequently, the present invention is not limited to the specific *gdhA* promoter from *Aspergillus awamori* disclosed herein but also relates to the promoter of any glutamate dehydrogenase gene from a fungus of the genus *Aspergillus* with the proviso that it is not from *Aspergillus nidulans*. Examples of said *Aspergilli* include *Aspergillus awamori*, *Aspergillus niger*, *Aspergillus oryzae* and *Aspergillus sojae*. In a preferred embodiment, the invention relates to a promoter of a glutamate dehydrogenase gene from *Aspergillus awamori* or *Aspergillus niger*. In a more preferred embodiment, the invention relates to a promoter of a glutamate dehydrogenase gene from *Aspergillus awamori*. The

4 14.05.95.00

use of the novel nucleotide sequence shown in SEQ ID No. 1 or a portion thereof as probe is also a object of the present invention. The term "a portion thereof" denotes any part of the nucleotide sequence of SEQ ID No.1 that is functional as a probe.

Another object of the present invention is a new DNA sequence, purified and isolated, that encodes a glutamate dehydrogenase protein and that comprises a nucleotide sequence - or a complementary strand thereof - selected from the group consisting of: (a) the nucleotide sequence numbered 741-2245 in the enclosed SEQ ID No. 1; and (b) a nucleotide sequence that hybridizes under stringent conditions to that defined in (a) with the proviso that the sequence is not the *gdh* gene from *Aspergillus nidulans*.

In a preferred embodiment, the nucleotide sequence encoding a glutamate dehydrogenase is the sequence defined in (a), i.e. the nucleotide sequence numbered as 741-2245 in SEQ ID No. 1. The present invention is not limited, however, to the specific *gdhA* gene from *Aspergillus awamori* disclosed herein but also relates to any glutamate dehydrogenase gene from a fungus of the genus *Aspergillus* with the proviso that it is not from *Aspergillus nidulans*. In a preferred embodiment, the invention relates to the DNA sequences encoding glutamate dehydrogenase from *Aspergillus awamori* or *Aspergillus niger*. In a more preferred embodiment, the invention relates to the DNA sequences encoding glutamate dehydrogenase from *Aspergillus awamori*.

Another object of the invention are the novel proteins encoded by any of the DNA sequences defined above. In a preferred embodiment, this protein has the amino acid sequence shown in the enclosed SEQ ID No. 2. But are also included in the present invention any glutamate dehydrogenase from a fungus of the genus *Aspergillus* with the proviso that it is not from *Aspergillus nidulans*, more preferably a glutamate dehydrogenase from *Aspergillus awamori* or *Aspergillus niger*, and still more preferably a glutamate dehydrogenase from *Aspergillus awamori*.



The invention further relates to the use of the glutamate dehydrogenase promoters above described for the expression of recombinant proteins in filamentous fungi. Certain

5 glutamate dehydrogenases from several microorganisms are already known and their genes have been disclosed, in particular the glutamate dehydrogenase A (gdhA) gene from Aspergillus nidulans (A.R. Hawkins et al., Mol. Gen. Genet. 1989, 218(1), pp. 105-111). However, to the best of our

10 knowledge, there has been no disclosure up to now of the expression of a recombinant protein making use of the gdhA promoter from A. nidulans nor has it ever been mentioned that it might be useful for improving the expression of recombinant proteins in filamentous fungi. As shown in the

15 examples below, the glutamate dehydrogenase promoter from Aspergillus awamori has proven to be very strong in promoting transcription of heterologous genes. Therefore, this promoter as well as related gdh promoters from Aspergilli are expected to drive high-level transcription of

20 genes and thus are expected to be of use in the expression of recombinant proteins in filamentous fungi. It is thus a further object of the present invention the use of a promoter from a glutamate dehydrogenase gene from a fungus of the genus Aspergillus for the expression of recombinant

25 proteins in filamentous fungi. Preferably, the gdh promoter is from a fungus of the genus Aspergillus with the proviso that it is not from Aspergillus nidulans, more preferably it is from Aspergillus awamori or Aspergillus niger, still more preferably it is from Aspergillus awamori, and particularly

30 preferably it is one of the novel gdh promoters described above.

There is in principle no limitation on the desired recombinant protein to be expressed. Examples of such

35 desired proteins (which term, as used herein, includes proteins and smaller polypeptides) include, but are not limited to, enzymes, hormones, cytokines, growth factors,

structural proteins, plasma proteins and others. A non-limiting list of examples of proteins that can be expressed includes human proteins such as interferons, interleukins, tissue plasminogen activator, serum albumin, growth hormone, and growth factors. Other proteins can be of non-human origin such as lipases of both fungal and non-fungal origin, proteases, thaumatins, bovine chymosin, etc. Polypeptides, which can be of human and non-human origin, include calcitonin, glucagon, insulin, nerve growth factor, epidermal growth factor, the anticoagulant Hirudin and analogs such as R3-hirulog.

A further object of the present invention are the DNA constructions that comprise: a) a promoter from a glutamate dehydrogenase gene from a fungus of the genus Aspergillus; b) a DNA sequence encoding a protein normally expressed from a filamentous fungus or a portion thereof; c) a DNA sequence encoding a cleavable linker peptide; and d) a DNA sequence encoding a desired protein. In a preferred embodiment, the promoter under a) comprises a gdh promoter from a fungus of the genus Aspergillus with the proviso that it is not from Aspergillus nidulans, more preferably it is from Aspergillus awamori or Aspergillus niger, still more preferably it is from Aspergillus awamori, yet more preferably it comprises any of the new promoters described above, and more particularly it comprises the nucleotide sequence 1-740 in SEQ ID No. 1. The DNA sequence under b) encodes a protein normally expressed from a filamentous fungus or a portion thereof that is functional, i.e. that is capable of producing increased secretion of the desired protein. Examples of such protein under b) include glucoamylase,  $\alpha$ -amylase and aspartyl proteases from Aspergillus awamori, Aspergillus niger, Aspergillus oryzae and Aspergillus sojae, cellobiohydrolase I, cellobiohydrolase II, endoglucanase I and endoglucanase III from Trichoderma species, glucoamylase from Neurospora and Hemicola species, the protein B2 from Acromonium chrysogenum and a glutamate dehydrogenase from a

filamentous fungi. In a preferred embodiment, the DNA sequence under b) encodes a protein or portion thereof selected from the group consisting of: i) glucoamylase from Aspergillus awamori, Aspergillus niger, Aspergillus oryzae or Aspergillus sojae; ii) B2 from Acremonium chrysogenum; and iii) a glutamate dehydrogenase from a filamentous fungi; more preferably, the DNA sequence under b) encodes a protein or portion thereof selected from the group consisting of: i) glucoamylase from Aspergillus awamori, Aspergillus niger, Aspergillus oryzae or Aspergillus sojae; ii) B2 from Acremonium chrysogenum; and iii) a glutamate dehydrogenase from Aspergillus awamori or Aspergillus niger. The DNA sequence under c) encodes a cleavable linker peptide; as used herein, cleavable linker peptide means a peptide sequence which under certain circumstances allows the separation of the sequences bordering the cleavable linker, for example sequences that are recognized and cleaved by a protease or cleaved after exposure to certain chemicals. In a preferred embodiment, the DNA sequence under c) contains a KEX2 processing sequence. As mentioned above, the desired protein under d) can be in principle any recombinant protein. In a preferred embodiment, the DNA sequence under d) encodes thaumatin; particularly preferred constructions for the preparation of thaumatin include those wherein the DNA sequence encoding thaumatin under d) is the synthetic gene encoding thaumatin II coming from plasmid pThIX, which is disclosed in EP 684312.

Although in the context of the present invention it is preferred, when expressing a desired protein, to use the *gdh* promoters in fusion constructions, it is also possible to use a *gdh* promoter to express directly a desired protein. Therefore, it is a further object of the present invention the new DNA constructions that comprise a *gdh* promoter from a fungus of the genus Aspergillus operatively linked to a DNA sequence encoding the protein that it is desired to express. In a preferred embodiment, the *gdh* promoter is from

- a fungus of the genus Aspergillus with the proviso that it is not from Aspergillus nidulans, more preferably it is from Aspergillus awamori or Aspergillus niger, still more preferably it is from Aspergillus awamori, yet more preferably it is one of the new promoters described above, and more particularly it comprises the nucleotide sequence 1-740 in SEQ ID No. 1.

- As will be obvious to those skilled in the art of recombinant DNA technology, all the above DNA constructions may additionally contain other elements which include, but are not limited to, signal sequences, termination sequences, polyadenylation sequences, selection sequences, sequences that allow the replication of the DNA, etc. There is no limitation on the number and nature of these additional sequences and any of the known sequences for exerting these functions can in principle be used in the constructions according to the present invention. For example, as a signal sequence functional as a secretory sequence we can mention the signal sequences from glucoamylase,  $\alpha$ -amylase and aspartyl proteases from Aspergillus awamori, Aspergillus niger, Aspergillus oryzae and Aspergillus sojae, signal sequences from cellobiohydrolase I, cellobiohydrolase II, endoglucanase I and endoglucanase III from Trichoderma species, signal sequences from glucoamylase from Neurospora and Humicola species and the signal sequence from the protein B2 from Acremonium chrysogenum. In general it is preferred to use as signal sequence those derived from proteins secreted by the filamentous fungus used as expression host to express and secrete the recombinant protein or, in case fusion constructions are used, also those derived from the protein used as carrier protein. A termination sequence is a nucleotide sequence which is recognized by the expression host to terminate transcription. Examples include the terminators from the A. nidulans trpC gene, the A. awamori, A. niger, A. oryzae or A. sojae glucoamylase gene, the A. awamori, A. niger, A.

oryzae or A. sojae  $\alpha$ -amylase genes and the Saccharomyces cerevisiae cycl gene. A selection sequence is a sequence useful as selection marker to allow the selection of transformed host cells. In principle any known selection marker for the filamentous fungus that is intended to be used as host can be employed. Examples of such selection markers include genes conferring resistance to a drug such as an antibiotic (e.g. hygromycin or phleomycin) as well as auxotrophic markers such as argB, trpC, niaD and pyrG. A polyadenylation sequence is a nucleotide sequence which when transcribed is recognized by the expression host to add polyadenosine residues to transcribed mRNA. Examples include the polyadenylation sequences from the A. nidulans trpC gene, the A. awamori, A. niger, A. oryzae or A. sojae glucoamylase genes and the Mucor miehei carboxyl protease gene.

The present invention also relates to the filamentous fungus cultures capable of producing a recombinant protein that have been transformed with plasmids that contain any of the DNA constructions mentioned above. Examples of species of filamentous fungi that may be used as expression hosts include the following genera: Aspergillus, Trichoderma, Neurospora, Penicillium, Acromonium, Cephalosporium, Achlya, Phanerochaete, Podospora, Endothia, Mucor, Fusarium, Humicola, Cochliobolus, Rhizopus and Pyricularia. Particularly preferred are those cultures wherein the filamentous fungus is selected from a fungus of the genus Aspergillus, and more preferably it is selected from Aspergillus awamori, Aspergillus niger, Aspergillus oryzae, Aspergillus nidulans or Aspergillus sojae. In another preferred embodiment, the recombinant protein produced is thaumatin.

A further object of the present invention is to provide a process for producing a recombinant protein in a filamentous fungus that comprises the following steps: a) preparation of

an expression plasmid that contains a DNA construction as defined above; b) transformation of a strain of filamentous fungus with said expression plasmid; c) culture of the transformed strain under appropriate nutrient conditions to produce the desired protein, either intracellularly, extracellularly or in both ways simultaneously; and d) depending on each case, separation and purification of the desired protein from the fermentation broth. Preferred is the process wherein the recombinant protein produced is thaumatin.

The accompanying examples describe the identification and isolation of the glutamate dehydrogenase A gene and its promoter region from Aspergillus awamori. This was achieved using a probe from Neurospora crassa. The selection of a suitable DNA fragment from the glutamate dehydrogenase gene in Neurospora crassa to be used as a probe to get the homologous gene in Aspergillus awamori is not, however, straightforward. In this case, there were no clear homology sequences that could be detected, and therefore what was used was a 2.6 kb BamHI fragment that contained the Neurospora crassa gdh gene. This is a large fragment of DNA, and is certainly not the optimal size fragment. Ideally, one wants to use as a probe a highly homologous fragment of DNA, no more than 200-300 bp long. Here a much larger fragment (2600 bp) with undefined homology was used. Yet the present inventors managed to clone a sequence that was later on proven to be the gdh from Aspergillus awamori.

The accompanying examples also describe the application of the above described novel promoters and DNA constructions to the expression of the recombinant protein thaumatin in the filamentous fungus Aspergillus awamori. As shown in these examples, and as illustrated graphically in Figure 12, the expression system of the present invention offers several advantages over the prior art systems. On the one hand, it allows to reach concentrations of expressed protein of about

100 mg/l, which are one order of magnitude higher than the best described (for example, using the process described in EP 684312, concentrations of about 5-10 mg/l are attained; see I. Faus et al., Appl. Microbiol. Biotechnol., 1998, vol. 5 49, pp. 393-398). On the other hand, for a same carrier protein and a same fermentation time, the use of the promoter of the present invention leads to higher concentrations of expressed protein. And last but not least, with the constructions of the present invention it is 10 possible to use a more economical nitrogen source (ammonium sulfate) than the one that is commonly used (asparagine).

#### DEFINITIONS

- 15 The term "promoter" means a DNA sequence operative in a filamentous fungus capable of promoting transcription of a coding region when operatively associated therewith.
- 20 The term "recombinant protein" means a protein that is not expressed under standard normal conditions by the host, and that is only expressed by the host as a result of the introduction into said host of a DNA sequence that allows for the expression of said recombinant protein. This 25 recombinant protein can be fungal or non-fungal, and it can even be found in the non-recombinant host.

#### BRIEF DESCRIPTION OF THE DRAWINGS

- 30 Figure 1, parts A, B and C. Schematic representation of the steps involved in the construction of the B2KEX expression cassette.
- 35 Figure 2. Restriction map of a 28.7 kb region of A. awamori DNA including the *gdhA* gene. Map of phages FAN1 and FAN2. Thick lines indicate the overlapping zone between the two

phages containing the *gdhA* gene. pB10, pB5.5 and pB1.7 indicate the DNA fragments subcloned in the corresponding plasmids. B = BamHI, S = Sal I.

- 5 Figure 3. Restriction map of the 2.1 kb XbaI-BamHI fragment from pB5.5 plasmid that was sequenced. The 3' end of the *gdhA* gene was contained in the left region of the insert in pB1.7. B = BamHI, E = EcoRI, EV = EcoRV, P = PstI, S = SalI, X = XbaI.

10

Figure 4, parts A and B. Alignment of the deduced amino acid sequences of NADP-specific glutamate dehydrogenases of *A. awamori*, *A. nidulans* (Genebank accession number P18819), *N. crassa* (P00369), *S. cerevisiae* (P07262), *S. occidentalis* (P29507), *A. bisporus* (P54387), *S. typhimurium* (P15111), *E. coli* (P00370) and *C. glutamicum* (P31026). Identical amino acids are shadowed. Motifs a-i with several consecutive conserved residues are overlined.

15

- 20 Figure 5. Complementation of the *gdhA* mutation in two strains of *A. nidulans* with the *gdhA* gene of *A. awamori*. Part A: 1, *A. nidulans* A686 mutant; 2, transformant A686-4; 3, transformant A686-6; 4, transformant A686-7. Part B. 1, *A. nidulans* A699 mutant; 2, transformant A699-2; 3, transformant A699-3; and 4, transformant A699-4.

25

Figure 6. Primer extension identification of the 5' end of the *gdhA* gene transcript. One protected band (arrow) is observed in the lane corresponding to the extension reaction (lane Pe). G, A, T, C lanes correspond to the sequencing reactions of M13 phage from the -40 primer.

30

- Figure 7. Northern blot analysis of the transcripts of the *gdhA* and  $\beta$ -actin genes. A: hybridization with a probe internal to the *gdhA* gene (0.694 kb PvuII fragment). B: hybridization with the  $\beta$ -actin gene of *A. nidulans* as control.

35



Figure 8. Slot Blot analysis of the transcript of the A. awamori *gdhA* gene, during the course of a fermentation in MDFA medium with 1% glucose and 10 mM ammonium sulfate (part A). For comparative purposes, the transcript of the  $\beta$ -actin gene in the same RNA sample was also studied. Part B: relative level of the expression of the *gdhA* to the  $\beta$ -actin gene. Part C: NADP-dependent glutamate dehydrogenase activity in the same cultures from where the mRNAs were extracted.

10

Figure 9. Slot Blot analysis of the transcript of the A. awamori *gdhA* gene during the course of a fermentation in MDFA medium with different nitrogen sources (part A). The medium contained ammonium sulfate 10 mM as a control and glutamic acid, glutamine, sodium nitrite, sodium nitrate and asparagine as nitrogen source, all of them at a concentration of 10 mM. The transcript of the  $\beta$ -actin gene was also studied for comparative purposes. Part B: Relative level of expression of the *gdhA* to the  $\beta$ -actin gene.

20

Figure 10, parts A, B and C. Schematic representation of the steps involved in the construction of the GDH expression cassette.

25 Figure 11, parts A and B. Schematic representation of the steps involved in the construction of the GPD expression cassette.

Figure 12. Production (expressed as concentration CT of secreted protein in mg/l) of thaumatin from A. awamori strains TB2b1-44 and TGDTh-4 in fermentor studies. The medium used was MDFA supplemented with the components described below. Empty squares: Strain TB2b1-44; 6.0% sucrose, pH 6.2, fedbatch with asparagine. Empty circles: TB2b1-44, 6.0% sucrose, pH 6.2, fedbatch with ammonium sulfate. Filled triangles: Strain TGDTh-4; 6.0 % sucrose, pH 6.2, fed-batch with ammonium sulfate.

35

DETAILED DESCRIPTION OF ONE MODE OF CARRYING OUT THE INVENTION

- 5 This section describes the application of the new promoter and constructions described in the present invention to the preparation of recombinant thaumatin. The teachings of the examples below can be applied to the expression and production of any other recombinant protein and thus these  
10 examples should not be construed as limiting the scope of the present invention in any way.

A: CONSTRUCTS:

- 15 The starting point for all of the constructs that have been prepared in the present patent application is plasmid pThIX, which is described in European patent application EP 684312. This plasmid contains: (i) a sulfanilamide resistance marker; (ii) a DNA sequence which encodes a fusion protein comprising  
20 in his turn (a) the synthetic gene encoding thaumatin II, (b) a spacer sequence which in turn contains a KEX2 processing sequence, and (c) the complete glucoamylase gene (genomic) of Aspergillus niger; (iii) the signal sequence ("pre") and the "pro" sequence of the glucoamylase gene (glaA) of Aspergillus  
25 niger, and finally (iv) the promoter region sequence of the glucoamylase gene (glaA) of Aspergillus niger.

- In the context of the present invention three new expression cassettes were prepared, which contained: (i) a drug  
30 resistance marker (most of the times it was a phleomycin resistance marker); (ii) a DNA sequence which encodes a fusion protein comprising in his turn (a) the synthetic gene of thaumatin II, (b) a spacer sequence which in turn contains a KEX2 processing sequence, and (c) a cDNA sequence that  
35 encodes most of the B2 protein (except sequences in the COOH end) from Acronium chrysogenum; (iii) the signal sequence of the B2 gene of Acronium chrysogenum and (iv) three

different promoter regions.

In all the cloning and sub-cloning manipulations described in this patent application, Escherichia coli DH5a served as the recipient strain for high-frequency plasmid transformation. E. coli WK6 was used as host for obtaining single-stranded DNA from pBluescript plasmids for sequencing purposes.

#### A1. Construction of the expression cassette B2KEX

10

Protein B2 is an extracellular protease produced by the filamentous fungus Acremonium chrysogenum. This protein is expressed and secreted in the late stages of growth of Acremonium chrysogenum (between 120 and 144 hours after the start of growth).

15

Plasmid pJE1A (Laboratory of Prof. Juan-Francisco Martín, Universidad de León, León, Spain) contains the promoter region, leader peptide (including the signal sequence) and coding region of the B2 gene from Acremonium chrysogenum. The gene itself has 1298 base pairs and two introns. These two introns are not present in the sequence that has been subcloned in pJE1A, since these subcloned sequences were obtained from a cDNA. Upstream from the ATG start point of translation there is a promoter region of 477 base pairs. When Acremonium chrysogenum is grown in a defined medium which contains sucrose and glucose as carbon sources and asparagine as nitrogen source, the gene is expressed at its highest levels between 72 and 96 hours of growth.

30

The steps involved in the construction of the B2KEX cassette are detailed in Figure 1 (parts A-C). Plasmid pJE1A was digested sequentially with BamHI and NcoI, releasing a 560 bp fragment that was purified from a 0.8% agarose gel. This fragment contains most of the coding region of the B2 gene, but excludes the active center of the protein. Similarly, plasmid pJL43b (J.L. Barredo, Ph.D. Thesis, Universidad de

35

08047543.1002000

León, León, Spain) was also digested with BamHI and NcoI, releasing a large fragment (3740 bp), which was purified from a 0.8% agarose gel. This fragment was ligated with the 560 bp BamHI-NcoI fragment from pJEL1A, yielding plasmid p43bB2CT (4300 bp).

Plasmid p43bB2CT was digested with NcoI, treated with the Klenow fragment of DNA polymerase I (in order to obtain blunt ends) and then digested with StuI, yielding a fragment of 3874 bp that was also purified from a 0.8% agarose gel. The single-stranded oligonucleotides ThS1 and ThS2 (sequences shown below) were used, using plasmid pThIX as a template, to amplify by polymerase chain reaction (PCR) the KEX2-like and thaumatin sequences present in pThIX. The first 18 nucleotides present in ThS1 correspond to the KEX2-like sequence.

ThS1: 5'- CGA ATG AAA AGG AAA AGG ATGCCACCTTCGAG - 3'

Arg Met Lys Arg Lys Arg

ThS2: 5'- TTA TTA GGC GGT GGG GCA - 3'

A 655 bp DNA fragment was obtained by PCR using plasmid pThIX as the template and ThS1 and ThS2 oligonucleotides as primers. This DNA fragment was ligated with the previously obtained fragment from p43bB2CT, yielding plasmid p43bB2CTTh. This plasmid (aprox. 4530 bp) contains part of the B2 protein gene fused to a KEX-2 sequence and to the synthetic gene encoding thaumatin II. The transcription termination signal present in this construct is the terminator sequence from the *cycl* gene of *Saccharomyces cerevisiae*.

Plasmid p43bB2CTTh was digested with BamHI, treated with calf intestinal alkaline phosphatase (CIP) and purified from a 0.8% agarose gel. A 900 bp BamHI-BamHI fragment from pJEL1A was also isolated. Subsequent ligation of these two DNA fragments generated plasmid pB2KEX (5430 bp). The 900 bp

BamHI-BamHI fragment from pJE1A contains the B2 gene promoter sequence (477 bp), the leader peptide sequence (318 bp) and 107 bp of the amino terminal sequence of the B2 gene.

- 5 Plasmid pB2KEX was then digested with XbaI, treated with the Klenow fragment of DNA polymerase I (in order to obtain blunt ends) and then digested with SalI, yielding a fragment of 2400 bp that was purified in a 0.8% agarose gel. Plasmid pJL43b was digested with HindIII, also treated with the  
10 Klenow fragment of DNA polymerase I, and then digested with XhoI. A fragment of 4500 bp was purified as before. Finally, the two gel-purified fragments described above were ligated, generating plasmid pB2KTh (6900 bp; Fig. 1C).
- 15 On the final sub-cloning step, both plasmids pB2KTh and pJL43b1 were digested with SacI and StuI, yielding fragments of 5714 and 1305 bp, respectively, which were purified in a 0.8% agarose gel. These two fragments were then ligated, thus obtaining plasmid pB2KThb1 (7020 bp; Fig. 1C). Plasmid  
20 pJL43b1 is a derivative of plasmid pJL43b, where the promoter that drives expression of the phleomycin resistance gene (PpcbC from Penicillium chrysogenum) was substituted by the glyceraldehyde-3-phosphate dehydrogenase (gpd) promoter from Aspergillus nidulans (P. Punt et al., Gene 1990, vol. 93, pp.101-109).
- 25

This plasmid contains a cassette to express thaumatin that comprises: (i) a phleomycin resistance marker; (ii) a DNA sequence which encodes a fusion protein comprising in his  
30 turn (a) the synthetic gene of thaumatin II, (b) a spacer sequence which in turn contains a KEX2 processing sequence, and (c) a cDNA sequence that encodes most of the B2 protein (except sequences in the COOH end) from Acronium chrysogenum; (iii) the signal sequence of the B2 gene of  
35 Acronium chrysogenum and (iv) the promoter region of the B2 gene of Acronium chrysogenum. In this particular construct, expression of the phleomycin resistance gene

(phleo) is driven by the promoter of the glyceraldehyde-3-phosphate dehydrogenase gene from Aspergillus nidulans.

## A2. Construction of the expression cassette GDHT<sub>H</sub>

5

### A.2.1. Cloning of a DNA fragment of *Aspergillus awamori* containing the *gdhA* gene.

10 A. awamori ATCC 22342 was used as the source of DNA and RNA. A. nidulans mutants A686 (*gdhA1*, *yA2*, *methH2*, *galA1*) and A. nidulans A699 (*gdhA1*, *bia1*) (J.R. Kinghorn, J.A. Pateman, J. Gen. Microbiol. 1973, vol. 78, pp. 39-46) were obtained from the Fungal Genetics Stock Center, and were used for complementation studies with the *gdhA* gene from A.  
15 awamori. The partial glutamate auxotrophy of these two strains was confirmed by growth on media with glutamic acid or high ammonium sulfate concentrations (100 mM) as nitrogen source. Both *gdhA* mutants grow very poorly under high ammonium sulfate concentrations but show normal growth when  
20 glutamic acid is used as nitrogen source. E. coli NM539 served as host for Lambda GEM12 (Promega Co., Wis) phage derivatives.

Filamentous fungi were routinely maintained on solid Power  
25 sporulation medium (F. Fierro et al., Appl. Microbiol. Biotechnol. 1996, vol. 43, pp. 597-604) at 30°C for 3 days. A. awamori and A. nidulans seed cultures in CM medium (containing 20 g/l malt extract; 5 g/l yeast extract; 5 g/l glucose) were inoculated with 10<sup>6</sup> spores/ml and grown at 28°C  
30 in a rotary G10 incubator (New Brunswick Scientific, New Brunswick, N.J.) for 48 h. For *gdhA* transcript isolation and characterization studies, A. awamori cultures in MDFA medium (Y.Q. Shen et al., J. Antibiot. 1984, vol. 37, pp. 503-511) were incubated with a 15 % seed culture and grown at 30°C for  
35 48-72 h in a rotary shaker, as described above.

#### A.2.1.1. *Aspergillus awamori* genomic library

- A genomic library of total DNA of A. awamori ATCC 22342 was constructed in a Lambda GEM12 phage vector. Total DNA was extracted and partially digested with Sau3AI to obtain DNA fragments of between 17 and 23 kb. This DNA was purified by sucrose-gradient centrifugation, ligated to Lambda GEM12 phage arms, and packaged in vitro using a Gigapack III Gold packaging system (Stratagene) resulting in a total of  $8 \times 10^4$  recombinant phages.
- In the next step, and using as probe a 2.6 kb BamHI fragment containing the gdhA gene of Neurospora crassa (J.H. Kinnaird, J.R.S. Fincham, Gene 1983, vol. 26, pp. 253-260), two phages, FAN1 and FAN2, that gave a clear hybridization signal were isolated and purified by three rounds of infection. Restriction mapping of these two phages showed that they overlap in 7.2 kb. The total DNA region cloned in the two phages extended for 28.7 kb.
- BamHI fragments of 1.7, 5.5 and 10 kb were subcloned in pBluescript KS+ plasmid, giving rise to plasmids pB1.7, pB5.5 and pB10, as shown in Figure 2. They were then sequenced by generating ordered sets of deletions with the Erase-a-base system (Promega Co., Wis.) by digestion with exonuclease III from appropriate ends, followed by removal of single-stranded DNA with S1 exonuclease. Sequencing of fragments of the gdhA gene was performed by the dideoxynucleotide chain termination method. For sequencing the cDNA clones containing the intron-exon junctions, reactions were performed with 90 ng of dsDNA using the GeneAmp PCR 2400 system coupled to the ABI-PRISM 310 automatic sequencer (Perkin Elmer). Computer analysis of nucleotide and amino-acid sequences were made with the DNASTAR software (DNASTAR, Inc., UK).
- Initial sequencing showed that an open reading frame (ORF1) occurred in the right end of the 5.5 kb insert of pB5.5 extending into the left region of the 1.7 kb BamHI fragment

of pBl.7, as shown in Figure 3. The 5.5 kb and 1.7 kb BamHI fragments were mapped in detail.

A 2.1 kb XbaI-XbaI fragment corresponding to the right end of plasmid pB5.5 was subcloned in pBluescript SK+ plasmid, creating plasmid pBSGh. More specifically, this 2.1 Kb XbaI-XbaI fragment was generated by digesting pB5.5 at an internal XbaI site and at a second XbaI site in the polylinker of pBSKS+ (and close to the BamHI site shown in Fig. 3).

A region of 2570 nt was sequenced in both strands by the dideoxynucleotide chain termination method. This region contained ORF1 (1380 bp), which started at an ATG located 740 bp downstream from the left end of the insert in pBSGh and extended until the end of the 5.5 kb BamHI fragment, with 60 additional bp into the adjacent 1.7 kb fragment. ORF1 was preceded by a 740 nucleotide region that contained the necessary signals required for transcription initiation and regulation (see SEQ. ID No. 1).

ORF1 contained two putative introns at positions 785-850 and 1414-1471 (following the numbering in SEQ ID No. 1) that showed lariat and 5' and 3' splicing sequences similar to those of other fungal introns (D.J. Ballance, *Yeast* 1986, vol. 2, pp. 229-236). The presence of the two introns was confirmed by sequencing the DNA regions corresponding to introns I and II obtained by PCR from a *A. awamori* cDNA library using as primers oligonucleotides I<sub>A</sub> and I<sub>B</sub> for intron I, and II<sub>A</sub> and II<sub>B</sub> for intron II (sequences shown below).

cDNA for these experiments was obtained from total RNA extracted as described above, from mycelia grown for 48 h in MDFA medium. The first and second cDNA strands were synthesized using a cDNA synthesis kit from Stratagene (La Jolla, Ca). This cDNA was used for PCR amplification of the fragments containing the exon-exon junctions by the following program: 1 cycle at 94°C for 5 min, 50°C for 1 min, 72°C for



1 min followed by 30 cycles at 94°C for 1 min, 50°C for 1 min, 72°C for 1 min and finally one cycle at 72°C for 8 min.

Oligonucleotides:

5

I<sub>A</sub> 5' ATG TCT AAC CTT CCT CAC 3'

I<sub>B</sub> 5' ACC CTT ACC ACC ACC CAT 3'

II<sub>A</sub> 5' CGC TTC TGT GTT TCC TTC 3'

II<sub>B</sub> 5' GTA CTT GAA CTT GTT GGC 3'

10

A.2.1.2. ORF1 encodes a putative NADP-dependent glutamate dehydrogenase

ORF1 encoded a protein of 460 amino acids (see SEQ ID No. 2) with a deduced molecular mass of 49.4 kDa and a pI value of 5.62. Comparison of the protein encoded by ORF1 with other proteins in the SWISS-PROT data base showed that the encoded protein has a high homology with NADP-dependent glutamate dehydrogenases of A. nidulans (84.7% of identical amino acids), N. crassa (74.4% identity), Saccharomyces cerevisiae (66.5% identity) and Schwanniomyces occidentalis (66.9% identity), as shown in Figure 4. The homology is extensive throughout the entire protein. All these proteins are NADP-dependent glutamate dehydrogenases that catalyze the reductive amination of  $\alpha$ -ketoglutarate, in the presence of ATP, to form L-glutamate. The protein encoded by ORF1 contains nine conserved motifs when compared with other fungal and yeast glutamate dehydrogenases. One of the conserved domains (amino acids 108-121) corresponds to a region implicated in the catalytic mechanism of the enzyme. The consensus sequence of this region is [LIV]-X(2)-G-G-[SAG]-K-X-[GV]-X(3)-[DNS]-[PL] (PROSITE PS00074). The lysine residue K<sup>114</sup> located in the glycine-rich region GGGR<sup>114</sup>GG corresponds to the lysine in the active center of Glu/Leu/Phe/Val (GLFV) dehydrogenases. Therefore, following standard fungal gene nomenclature, the gene encoded by ORF1 was named gdhA.

#### A.2.1.3. The cloned gene complements *A.nidulans* *gdhA* mutants

5 *A. nidulans* A686 and A699 strains were transformed by a known method (M.M. Yelton et al. Proc. Natl. Acad. Sci. USA 1984, vol. 81, pp. 1470-4) with plasmid pGDHaw (7.1 kb), which contains the *A. awamori* *gdhA* gene in a 2570 bp XbaI-XbaI fragment. This fragment contains also an upstream promoter region of 740 bp and a 322 bp region downstream from ORF1  
10 (*gdhA* gene). The 2570 bp XbaI-XbaI fragment was inserted into the XbaI site of the fungal vector p43gdh, which contains the phleomycin resistance marker under control of the *A. awamori* *gdhA* promoter as shown later in this patent application.

15 Seven transformants of *A. nidulans* A686 with the *A. awamori* *gdhA* gene and 15 transformants of *A. nidulans* A699 were analyzed on minimal medium supplemented with different concentrations (10, 50 and 100 mM) of ammonium sulfate as  
20 nitrogen source, and their growth was compared with that of wild type *A. nidulans*. As a control, growth was also tested on medium containing 10 mM glutamic acid. As shown in Figure 5, the untransformed *A. nidulans* mutants A686 and A699 grow very poorly in plates with 100 mM ammonium sulfate, whereas  
25 three randomly selected transformants grow very well in this medium. The residual growth of *A. nidulans* *gdhA* mutants A686 and A699 in ammonium sulfate as nitrogen source is known (J.R. Kinghorn, J.A. Pateman, Heredity 1973, vol. 31, pp. 427) and is due to the presence of a second glutamate  
30 dehydrogenase activity that allows partial growth of these mutants.

#### A.2.1.4. Glutamate dehydrogenase activity in the transformants

35 Nicotinamide adenine dinucleotide phosphate (NADP)-specific glutamate dehydrogenase (NADP-GDH) activity was assayed by

following the reductive amination of  $\alpha$ -ketoglutarate in the presence of ammonium and NADPH and expressed as units of enzyme activity per mg protein. The initial reaction velocity was estimated from the change in optical density at 340 nm in a Hitachi U-2001 spectrophotometer. One unit of glutamate dehydrogenase was defined as the activity that catalyzes the oxydation of one nanomol of NADPH per minute.

To confirm the complementation results, the NADP-dependent glutamate dehydrogenase activity was measured in the A. nidulans *gdhA* mutants A686 and A699, and in three randomly selected transformants complemented with the A. awamori *gdhA* gene. Results are shown in Table 1 and they clearly indicated that while the glutamate dehydrogenase activity in strains A686 and A699 was clearly below the detection levels, significant levels of glutamate dehydrogenase activity were obtained in the transformants with the A. awamori *gdhA* gene, particularly at 24 and 48 h of growth. Some of the transformants, like A699-4, showed relatively high levels of glutamate dehydrogenase activity, perhaps due to integration of more than one copy of the *gdhA* gene in the genome of this transformant.

-----  
 25 Table 1: NADP-dependent glutamate dehydrogenase activity (U/mg of protein), in the A. nidulans *gdhA* mutants A686 and A699, and in three transformants of each of these mutants with the A. awamori *gdhA* gene.  
 -----

30 strain	t = 24 h	t = 48 h	t = 72 h
<u>A. Awamori</u>	550	0	0
A686	0	0	0
A686-4	350	280	100
35 A686-6	340	200	80
A686-7	310	160	90
A699	0	0	0

A699-2	270	240	100
A699-3	410	420	400
A699-4	500	670	580

-----

5

A.2.1.5. Characterization of the promoter region of the *gdhA* gene

Analysis of the nucleotide sequence upstream from the ATG translation initiation codon revealed the presence of GTATA, CTATA and TCAATC sequences at positions -316, -61 and -17, respectively, with respect to the translation initiation codon, which may correspond to putative TATA and CAAT boxes involved in regulation of gene expression (see SEQ ID No. 1).

15

Identification of the transcription start point was performed by "primer extension" with 2 µg of mRNA obtained from mycelia grown in MDFA for 48 h, as shown in Figure 6.

20

Primer extension analysis using as primer the oligonucleotide "Pe" 5'-GGGGTCTCTCTGGAAGAGGGT-3' (corresponding to the nucleotide sequence 70 bp downstream from the ATG) revealed a single band in the extension reaction (Fig. 8). The 5'-end of the mRNA corresponds to a thymine (T) located 86 bp upstream of the ATG initiation codon.

25

A.2.1.6. The *gdhA* gene is transcribed as a monocistronic transcript of 1.7 kb, and its expression is regulated by nitrogen.

30

In order to perform expression studies, total RNA of *A. awamori* was obtained by the phenol-SDS method from mycelia grown for 12, 24, 48, 60 or 72 h in MDFA medium with 55.5 mM glucose and 10 mM ammonium sulfate as carbon and nitrogen sources, respectively. For nitrogen regulation studies, the MDFA base medium (without ammonium sulfate) was supplemented with glutamic acid, L-glutamine, sodium nitrite, sodium

35

nitrate and L-asparagine at 10 mM final concentrations.

For Northern analysis, total RNA (5 µg) was run on a 1.2% agarose-formaldehyde gel. The gel was blotted onto a nylon  
5 filter (NYTRAN 0.45; Schleicher and Schuell) by standard methods. The RNA was fixed by UV irradiation using an UV-Stratalinker 2400 lamp (Stratagene, La Jolla, Calif.).

For slot blotting, the RNA (5 µg) was loaded on a filter  
10 (NYTRAN 0.45) by vacuum in a Bio-Dot SF Microfiltration apparatus. (Slot Blotting, Bio-Rad). The RNA was fixed by UV irradiation as above. The filters were pre-hybridized for 3 h at 42°C in 50% formamide, 5 x Denhardt's solution, 5 x SSPE, 0.1% SDS, 500 µg of denatured salmon-sperm DNA per ml, and  
15 hybridized in the same buffer containing 100 µg of denatured salmon-sperm DNA per ml at 42°C for 18 h, using as probe an internal DNA fragment (0.694 kb PvuII) of the *A. awamori* *gdhA* gene. The filters were washed once in 2 x SSC, 0.1% SDS at 42°C for 15 min, once in 0.1 x SSC, 0.1% SDS at 42°C for 15  
20 min, and once more in 0.1 x SSC, 0.1% SDS at 55°C for 20 min and then autoradiographed with Amersham X-ray film. mRNA was purified from total RNA by using the Poly(A) Quick mRNA isolation kit (Stratagene, La Jolla, Calif.).

25 Northern analysis of the transcription of the *gdhA* gene revealed that it is strongly expressed as a 1.7 kb transcript (mRNA) with a size slightly larger than that of the  $\beta$ -actin gene mRNA, as shown in Figure 7. Since ORF1 contains 1380 nt, this size of the transcript indicates that the *gdhA* gene is  
30 expressed as a monocistronic transcript.

Since the same amount of total RNA was used in all lanes of Fig. 7, it was concluded that the *gdhA* steady state transcript levels in the cell are higher than those of the  $\beta$ -  
35 actin gene (arrows) indicating that the glutamate dehydrogenase A is expressed from a very efficient promoter.

To determine the pattern of expression of the *gdhA* gene during the time-course of growth of *A. awamori*, *gdhA* hybridizing RNA was compared to  $\beta$ -actin hybridizing RNA in MDFA medium with ammonium sulfate (Figure 8A) and expressed as the ratio of counts in the *gdhA*-hybridizing band to the  $\beta$ -actin hybridizing counts (Figure 8B). Results indicate that expression of both genes (*gdhA* and  $\beta$ -actin) is associated with the growth of *A. awamori* but whereas low steady state levels of  $\beta$ -actin mRNA remained in the cells until 96 hours of growth, the levels of glutamate dehydrogenase mRNA decreased drastically after 48 hours.

The glutamate dehydrogenase enzymatic activity detected when *A. awamori* is grown in MDFA medium with ammonium sulfate (10 mM) as nitrogen source at different times of the culture is shown in Fig. 8C. There is a sharp decrease in glutamate dehydrogenase activity between 24 and 48 h after start of growth, which is in good agreement with the decrease in transcript levels at this time of the culture, as shown in Fig. 8B.

Since glutamate dehydrogenase plays a central role in nitrogen utilization by *A. awamori*, it was also of interest to study if expression of *gdhA* was regulated by different nitrogen sources. As shown in Figure 9, very high *gdhA* transcript (mRNA) levels were obtained in media containing  $\text{NH}_4^+$ , or asparagine as sole nitrogen sources. Glutamic acid repressed transcription of the *gdhA* gene, whereas intermediate levels of expression (normalized with respect to the  $\beta$ -actin gene) were observed in media that contained nitrate, glutamine or nitrite as nitrogen source. These results show that the NADP-dependent glutamate dehydrogenase is subject to a strong nitrogen regulation at the transcriptional level.

The glutamate dehydrogenase activity in 24-hour cultures grown in MDFA medium containing different nitrogen sources,

- all at a concentration of 10 mM, is shown in Table 2. The highest activity (per ml of culture) was observed in cultures with  $\text{NH}_4^+$  or asparagine as nitrogen sources. Moreover, these two nitrogen sources favoured a strong growth of *A. awamori*.
- 5 When the results were expressed per mg of protein in the cell extracts, the highest specific activity was observed in MDFA medium with nitrate as the sole nitrogen source. This is due to the fact that in the presence of nitrate, *A. awamori* grows very slowly. The lowest activity was observed in MDFA medium
- 10 with glutamate as nitrogen source, confirming the results observed previously at the transcription level.

- 
- Table 2: NADP-dependent glutamate dehydrogenase activity in
- 15 *A. awamori* cultures grown for 24 h in MDFA medium supplemented with different nitrogen sources.
- 

	Nitrogen source (10mM)	Total Activity (U/ml)	Specific Activity (U/mg protein)
20	-----	-----	-----
	ammonium	1450	800
	glutamic acid	330	280
	glutamine	1100	600
	nitrite	990	660
25	nitrate	1150	1680
	asparagine	1300	720
	-----	-----	-----

- A.2.2. Construction of the expression cassette GDHTH
- 30

- Once the promoter region of the *gdhA* gene was located, a thaumatin expression cassette similar to the one described previously was constructed. Plasmid pBSGh was used as a template to obtain a 750 bp DNA fragment corresponding to the
- 35 promoter region of the *gdhA* gene. This fragment was obtained by DNA amplification using the oligonucleotides *gdh1* and *gdh2* and the Pfu enzyme (Stratagene).

gdh1: 5' - TTTT GTCGAC TTG CGA CGG CGT ATT GCT - 3'

Sal I

5 gdh2: 5' - TTTT CCATGG TCT GAA GGG GAG GAT TGA - 3'

Nco I

This amplified DNA fragment was digested with SalI and NcoI and purified in a 0.8% agarose gel.

10

Plasmid pJL43 (a derivative of pJL43b, Dr. José Luis Barredo, Ph.D. Thesis, Universidad de León, León, Spain) was digested with SalI and NcoI and a large fragment (3740 bp) was purified in a 0.8% agarose gel. This DNA fragment was then  
15 ligated with the SalI-NcoI fragment previously amplified, yielding plasmid p43gdh (4500 bp), where the pcbC promoter from *Penicillium chrysogenum* has been replaced by the gdhA promoter from *Aspergillus awamori*.

20

In the next step, plasmid p43gdh was digested with NcoI, treated first with the Klenow fragment of DNA polymerase I and then with calf-intestinal phosphatase (CIP). In parallel, a fragment of 1140 bp containing the B2 protein gene was amplified via the PCR technique, using plasmid pJElA as the  
25 template and oligonucleotides NTB2b and CTB2b as primers (sequences given below). This 1140 bp fragment was digested with BamHI and then treated with the Klenow fragment of DNA polymerase I. From this reaction mix a 425 bp DNA fragment containing the amino terminal sequences of the B2 gene was  
30 purified from a 1.0 % agarose gel. This fragment of DNA was ligated by blunt-end ligation to the fragment of DNA from p43gdh previously described, resulting in plasmid p43gdhB2, where the BamHI site that is shown in Figure 10 has been regenerated. This plasmid is 4925 bp long and contains the  
35 gdhA promoter fused "in frame" to the amino terminal portion of the B2 gene.



The next step in the construction of the complete expression cassette was the addition of the second portion of the B2 gene, the KEX2 sequence and the synthetic thaumatin II gene. For this part of the work, plasmid pB2KEX was used.

5

pB2KEX was sequentially digested with XbaI, treated with the Klenow fragment from DNA polymerase I and finally digested with BamHI. A fragment of 4637 bp was purified from a 0.8% agarose gel. In parallel, plasmid p43gdhB2 was sequentially  
10 digested with SalI, treated with the Klenow fragment from DNA polymerase I and finally digested with BamHI. A fragment of 1173 bp was purified from a 0.8% agarose gel. The ligation of these two fragments yielded plasmid pGDHth (5810 bp), where a new SalI site was created. This allows for the excision of  
15 the complete GDHth cassette as a 2670 bp SalI-SalI fragment.

Starting with plasmid pGDHth, two new plasmids were constructed. The first one was p43GDth, constructed as follows. Plasmid pJL43 was linearized by digestion with SalI  
20 and ligated to a 2170 bp SalI-DraI fragment from pGDHth (see Fig. 10, part B).

Similarly, plasmid pGD71 was constructed as follows: plasmid pAN7-1 (P.J. Punt et al., J. Biotechnol. 1990, vol. 17, pp.  
25 19-34) was sequentially digested with XbaI, treated with the Klenow fragment from DNA polymerase I, and finally digested with HindIII, and purified from a 0.8% agarose gel. In parallel, plasmid pGDHth was digested with Ec1136II (or SacI\*, a variant of SacI from Fermentas that recognizes the  
30 standard SacI restriction site but leaves a blunt end), HindIII and DraI. A fragment of 2175 bp was purified from an agarose gel. Ligation of these two fragments yielded plasmid pGD71 (see Fig. 10, part C).

35 Plasmids p43GDth and pGD71 contain a cassette to express thaumatin that comprises: (i) a DNA sequence which encodes a fusion protein comprising in his turn (a) the synthetic gene

of thaumatin II, (b) a spacer sequence which in turn contains a KEX2 processing sequence, and (c) a cDNA sequence that encodes most of the B2 protein (except sequences in the COOH end) from Acremonium chrysogenum; (ii) the signal sequence of the B2 gene of Acremonium chrysogenum, (iii) the promoter region from the Aspergillus awamori glutamate dehydrogenase A gene, and (iv) a drug resistance gene that can be used as a transformation marker. Plasmid p43GDTh has the phleomycin resistance gene (phleo) driven by the the pcbC promoter from Penicillium chrysogenum. Plasmid pGD71 contains the hygromycin B resistance gene driven by the glyceraldehyde-3-phosphate dehydrogenase promoter from Aspergillus nidulans.

### A.3. Construction of the expression cassette GPDTh

The expression cassette GPDTh is similar to the expression cassette B2KEX, except that the B2 promoter from Acremonium chrysogenum has been replaced by the promoter from the glyceraldehyde-3-phosphate dehydrogenase (named "gpd" from now on) gene from Aspergillus nidulans.

The complete promoter region of the gpd gene is present in plasmid pAN52-1 (P.J. Punt et al., J. Biotechnol. 1990, vol. 17, pp. 19-34). A SacI-NcoI fragment (880 bp) from pAN52-1 has been subcloned, generating pJL43b1.

Plasmid pJL43b1 was digested with NcoI and treated first with the Klenow fragment of DNA polymerase I and then with calf-intestinal phosphatase (CIP), as shown in Figure 11. In parallel, a 1140 bp fragment of DNA was obtained by DNA amplification using the PCR technique, using pJEL1A as template and oligonucleotides NTB2b and CTB2b as primers. This fragment of DNA was digested with BamHI and treated with the Klenow fragment from DNA polymerase I, yielding a fragment of 425 bp that was purified from a 0.8% agarose gel. The final ligation reaction yielded plasmid pblB2 (see Fig. 11).

NTB2b: 5' - ATG CGT GCT GCT ACT CTC - 3'

CTB2b: 5' - CTG GCC GTT GTT GAT GAG - 3'

- 5 As with the GDH<sup>th</sup> cassette, the next step in the construction of a complete expression cassette was the addition of the second portion of the B2 gene, the KEX2 sequence and the synthetic thaumatin II gene. For this part of the work, plasmid pB2KEX was once again used.

- 10 pB2KEX was sequentially digested with XbaI, treated with the Klenow fragment from DNA polymerase I and finally digested with BamHI. A fragment of 4637 bp was purified from a 0.8% agarose gel. In parallel, plasmid pblB2 was sequentially  
15 digested with BamHI and Ecl136II (or SacI\*) (leaves blunt ends), and a 1300 bp fragment was purified from a 0.8% agarose gel. The ligation of these two fragments yielded plasmid pGPD<sup>th</sup> (5800 bp).

- 20 In the next step, the GPD<sup>th</sup> cassette was isolated from pGPD<sup>th</sup> by digestion with Ecl136II (or SacI\*), HindIII and DraI, yielding a DNA fragment 2800 bp long. In parallel, plasmid pB2KThb1 was sequentially digested with BamHI, treated with the Klenow fragment from DNA polymerase I and finally  
25 digested with HindIII. A 4500 bp fragment was isolated from a 0.8% agarose gel. The plasmid resulting from the ligation of these two fragments was named pGPTHb1.

- This plasmid contains a cassette for the expression of  
30 thaumatin that is identical to the expression cassette B2KEX except that the promoter from the B2 gene of Acremonium chrysogenum has been replaced by the promoter from the *gpd* gene from Aspergillus nidulans.

- 35 B. Strains used and transformation protocol

Aspergillus awamori strain NRRL312 was obtained from the

- American Type Culture Collection (ATCC). Using standard mutagenesis techniques with nitrosoguanidine (NTG), a derivative of this strain was obtained, and was named LpR66. This mutant strain secretes into the growth medium an inactive exoprotease aspergillopepsin A (named "pepA" from now on). In all of the transformation experiments that are described below the strain that was used was Aspergillus awamori strain LpR66.
- 10 The three expression cassettes that have been described previously were used to transform Aspergillus awamori strain LpR66.

- In all single transformation experiments, the antibiotic phleomycin was used as the selection marker. Strain LpR66 can grow in plates that contain 20 µg/ml of phleomycin. Therefore, all transformants were selected in plates with 25 µg/ml of the antibiotic. The regeneration medium that was used is TSAS, which contains 30 g/l of Triptone-Soja (Difco),
- 20 103 g/l of sucrose and 1.5% agar (Difco).

- The transformation protocol was similar to the one described by Yelton (see above) with some modifications. A plate containing Power medium was inoculated with  $10^7$  spores. This
- 25 plate was incubated for 72 hours at 30°C, at which point the spores were scraped from the plate and were inoculated in 100 ml of CM medium (500 ml shake flask). Incubation was for 16-18 hours at 250 rpm and 28°C. The mycelium obtained from this growth was filtered through a 30 µm nylon filter (Nytal) and
- 30 washed with 10 mM sodium phosphate buffer (pH 5.8) which also contained 0.6 M magnesium sulfate. One gram of mycelium was re-suspended in "protoplast buffer" (10 mM sodium phosphate buffer (pH 5.8) which also contained 1.2 M magnesium sulfate). An equal volume of buffer containing the enzyme
- 35 "Lysing" (Sigma) was added, yielding a final concentration of 3 mg/ml of the enzyme. The mycelium solution was left to incubate for 3-4 hours at 100 rpm and 30°C until protoplasts

were formed. Protoplast formation was monitored by visual inspection using a light microscope. Protoplasts were filtered, washed and finally resuspended in STC solution, to a final concentration of  $10^8$  protoplasts/ml.

5 100  $\mu$ l of protoplast solution was mixed with 10-20  $\mu$ g of DNA and left in ice for 20 minutes. After this time interval, 500  $\mu$ l of PTC were added, and left at room temperature for another 20 minutes. Then, 600  $\mu$ l of STC medium were added and  
10 the transformation mix was aliquoted in different test tubes. Finally, the phleomycin antibiotic solution and TSAS medium that contained agar were added. The contents of the tubes were gently homogenized and added to TSAS plates that contained phleomycin. Plates were incubated at 30°C until the  
15 transformants were visualized as individual colonies. When hygromycin B was used as selection marker, a similar protocol was used.

The linearization of all the plasmids that have been  
20 described in this work gave a 4-fold increase in the efficiency of transformation as compared to transformations performed with plasmids that had not been linearized. Therefore, in most transformation experiments the plasmids were used linearized.

25 Several transformants were obtained and analyzed. Initial screens were performed in plates containing 25  $\mu$ g/ml of phleomycin. Confirmation screens were then performed using phleomycin concentrations as high as 200  $\mu$ g/ml.

30 Transformants were analyzed by PCR to detect whether the thaumatin II gene had been incorporated into their genome essentially as described (cf. EP 684312). Those transformants that were positive were then further analyzed for expression  
35 of thaumatin by immunoblot analysis and ELISA (enzyme-linked immunoassay) also as described (cf. EP 684312).

C: Recombinant strains that produce thaumatinC.1. Materials and methods5 C.1.1. Culture media

CM medium: malt extract, 5 g/l; yeast extract, 5 g/l; glucose, 5 g/l.

10 SMM medium: 8% sodium citrate; 1.5%  $(\text{NH}_4)_2\text{SO}_4$ ; 0.13%  $\text{NaH}_2\text{PO}_4 \cdot 2\text{H}_2\text{O}$ ; 0.2%  $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ ; 0.1% Tween 80; 0.1% uridine, 0.1% antifoam AF and 7% soya milk. The carbon source (glucose, sucrose, maltose, etc.) is present at a final concentration of 15%. The pH of the medium is adjusted to 6.2  
15 with  $\text{H}_2\text{SO}_4$ .

MDFA medium: 1.2% L-asparagine; 0.8% of salt solution I [2%  $\text{Fe}(\text{NH}_4)_2(\text{SO}_4)_2 \cdot 6\text{H}_2\text{O}$ ]; and 14.4% of salt solution II [10.4%  $\text{K}_2\text{HPO}_4$ ; 10.2%  $\text{KH}_2\text{PO}_4$ ; 1.15%  $\text{Na}_2\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ ; 0.2%  $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ ; 0.02%  $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$ ; 0.005%  $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ ; 0.05%  $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$ ]. The carbon source used was either maltose (usually 6.5%) or a mix of sucrose (3.6%) and glucose (2.7%). Other amounts of carbon source are indicated in each experiment that is described. The initial pH of this medium is 6.5.

25

C.1.2. Fermentation analysis

Growth and expression studies were conducted in SMM and MDFA media, first in shake flasks, and later in several fermentors  
30 equipped with measurement and control systems for the following variables: stirring, dissolved oxygen, pH, antifoam and culture level.

Experiments were conducted in 1-liter shake flasks with a  
35 working volume of 150 ml. Inoculation was to a final concentration of  $3 \times 10^5$  spores/ml. Stirring was at 150 rpm, and the incubation temperature was 30°C. The media used was

either SMM or MDFA.

- The experiments conducted in the fermentor were analogous to the ones in shake flasks, except that the pH of the medium was maintained constant at a pre-set value, and adjusted by the automatic addition of either 30% NaOH or 0.5N H<sub>2</sub>SO<sub>4</sub>.

### C.1.3. Analytical methods

- 2-10 ml samples were taken at different times from the fermentation culture and processed to determine the dry weight, thaumatin, maltose and glucose concentrations that were present.
- Dry weight was determined by passing a sample through a pre-filter (Nucleopore, Cat.No. 211114). The biological material retained in the pre-filter was washed with 40 ml of pure ethanol and 50 ml of distilled water. It was then incubated at 90°C until a constant weight could be recorded. The filtrate was aliquoted and frozen for further analysis.

- Thaumatococcus concentration in the culture broth was determined by an enzyme-linked immunoassay (ELISA) and by immunoblotting (Western blot) analysis, essentially as described (cf. EP 684312), using an anti-thaumatococcus polyclonal antibody. For immunoblotting, samples were sometimes concentrated as follows: 500 µl of filtrate were mixed with an equal volume of 10% trichloroacetic acid (TCA), and frozen for 12 h. The sample was then allowed to regain room temperature and centrifuged in a table-top centrifuge (15,000 rpm; 20 min. 4°C). The pellet that is recovered contains all the proteins that were present in this sample. The pellet was then resuspended in protein loading buffer, boiled for 5 minutes, and subjected to SDS-PAGE as described (cf EP 684312).

- Approximately 1 ml of filtrate was used for glucose/maltose determination. Glucose levels were determined using a SIGMA

DIAGNOSTICS kit (Procedure number 510).

Maltose concentration in the culture broth was determined as follows: 250  $\mu$ l of sample filtrate were placed in a test-tube that had been previously chilled; 1.250 ml of anthrone solution (prepared by dissolving 2 g anthrone in 50 ml absolute ethanol and then adding 950 ml of 75%  $H_2SO_4$ ) were then added, and the sample was kept chilled for five minutes. The sample was then transferred to a boiling water bath, and incubated for 10 minutes. Finally the samples were once again chilled and the absorbance read at 625 nm. Maltose concentrations were determined by comparison to a calibration curve generated by measuring the absorbance of maltose solutions of known concentrations (range: 0 - 0.2 g/l).

## C.2. Thaumatin producing strains

### C.2.1. Strain TB2bl-44

This strain is a derivative of Lpr66 that was obtained by transformation of the aforementioned LpR66 strain with the expression plasmid pB2KTh-b1. This expression cassette contains the synthetic thaumatin II gene under the control of the promoter of the B2 protein from Acromonium chrysogenum. In shake-flask cultures with MDFA medium this strain secretes 6-8 mg thaumatin/l.

Further optimization studies were performed in a 5-liter New Brunswick fermentor. The inoculum was obtained by growing the strain for 40 hours at 30°C in CM medium. 450 ml of this inoculum were then used to seed the 5-liter fermentor (working volume of 4.5 liters). RPMs were between 250 and 500, and varied according to the oxygen status of the system, which was always set at 30%.

Different parameters were tested, such as the pH of the medium and the carbon and nitrogen sources. Representative



experiments are described in Figure 12:

1. Growth in MDFA medium with 6.0% sucrose and L-asparagine as the nitrogen source. The set-point for the pH was set at 6.2, and a fed-batch system was installed. Feedings were done at 36, 48, 60 and 72 hours after the beginning of the fermentation. In each feeding, 45 ml of a 0.5 g/ml sucrose solution were added.
2. The conditions were identical to those described under 1 above, but L-asparagine was replaced by ammonium sulfate (the molar amounts were the same in both experiments) as the nitrogen source.
- The best productivity was obtained with the conditions described under 1 above, with asparagine as nitrogen source, and with 6% sucrose as the carbon source, with four "feedings" of sucrose every 12 h after 36 h of fermentation. Under these conditions, yields of 100 mg thaumatin/l were obtained.

#### C.2.2. Strain TGDTh-4

- This strain was deposited according to the Budapest Treaty with Access No. CECT20241 on March 25, 1998 (25.03.98) in the following institution:

Colección Española de Cultivos Tipo (CECT)  
Edificio de Investigación, planta baja, no. 34  
Universidad de Valencia  
Campus de Burjasot  
46100 Valencia, Spain

- It is a derivative of Lpr66 which was obtained by transformation of the aforementioned Lpr66 strain with the expression cassette p43GDTh. This expression cassette contains the synthetic thaumatin II gene under the control of

the promoter of the *gdhA* gene from Aspergillus awamori. In shake-flask cultures with MDFA medium (with 6.0% sucrose) this strain secretes 6-8 mg thaumatin/l.

Experiments were also conducted in the controlled environment of a 5-liter New Brunswick fermentor, as described before for strain TB2b1-44. Ammonium sulfate was used in place of asparagine as nitrogen source, at the same molar levels. In this experiment, also shown in Figure 12, the following conditions were tested: strain TGDTh-4 was grown in MDFA medium supplemented with 6% sucrose and ammonium sulfate as nitrogen source. The pH set-point was 6.2. and a fed-batch system was also installed. Feedings were done at 36, 48, 60 and 72 h after the beginning of the fermentation. In each feeding, 45 ml of a 0.5 g/ml sucrose solution were added.

The results (Fig. 12) indicate that the production of thaumatin is also in the order of 100 mg/l, but with the added advantage of having an earlier production and the use of a more economical nitrogen source. Therefore, it is concluded that the glutamate dehydrogenase promoter from Aspergillus awamori is more efficient than the B2 protein promoter from Acremonium chrysogenum.

#### 25 C.2.3. Strain TGP-3

This strain is a derivative of Lpr66 which was obtained by transformation of the aforementioned LpR66 strain with the expression cassette pGPTb1. This expression cassette contains the synthetic thaumatin II gene under the control of the promoter of the *gpd* gene from Aspergillus nidulans. In shake-flask cultures with MDFA medium this strain secretes 9-10 mg thaumatin/liter.

#### 35 C.2.4. Double transformants

Strains TB2b1-44 and TGP-3 were re-transformed with

expression plasmid pGD71, which contains the thaumatin gene under control of the glutamate dehydrogenase promoter from A. awamori and a hygromycin B resistance gene as a selection marker for transformation experiments. A battery of different transformants (see Table 3) was analyzed in shake flask experiments. It was shown that re-transformation of strain TGP-3 did not result in better producing strains. However, re-transformation of TB2b1-44 did result in better producing strains when cultured in shake-flasks under the standard conditions mentioned before.

Table 3: Production of thaumatin in shake flasks by retransformed strains grown in MDFA medium for 96 h. Quantification by ELISA. All strains were retransformed using hygromycin B resistance as selection marker.

	Transformant	Production (mg/l)	Original strain
20	TGP3-GD1	2.08	TGP3
	TGP3-GD2	0.40	TGP3
	TGP3-GD3	9.44	TGP3
	TGP3-GD4	8.25	TGP3
	TGP3-GD5	0.40	TGP3
25	TGP3-GD6	9.71	TGP3
	TB2b1-44-GD1	3.84	TB2b1-44
	TB2b1-44-GD2	0.00	TB2b1-44
	TB2b1-44-GD3	9.85	TB2b1-44
	TB2b1-44-GD4	11.10	TB2b1-44
30	TB2b1-44-GD5	11.82	TB2b1-44
	TB2b1-44-GD6	10.75	TB2b1-44
	TB2b1-44-GD7	10.52	TB2b1-44
	TB2b1-44-GD8	8.09	TB2b1-44
	TB2b1-44-GD9	7.13	TB2b1-44

35

D: Purification of recombinant thaumatin

Two procedures were employed for the purification of recombinant thaumatin. In the first one the fermentation broth was simply clarified, concentrated and diafiltered, yielding a concentrated and cleaner extract that was used for sensory experiments to ascertain the sweet profile of the recombinant thaumatin. The second procedure involved a classic purification protocol that yielded pure thaumatin.

10 D.1. Clarification, concentration and diafiltration of the fermentation broth

Biomass was removed by filtration through filter paper. The filtrate was collected in a filtering flask that was submerged in ice. The clarified broth was then centrifugated at 6000 rpm for 15 minutes at 4°C.

The clarified fermentation broth was further concentrated by ultrafiltration using a ProFlux™ M12 Tangential Filtration System. The system configuration was: base unit, level switch, 2.5 l reservoir, cooling coil, inlet and outlet pressure transducers, secondary pump, one Spiral-wound membrane cartridges S1Y3 (Molecular weight cut-off 3,000 Daltons).

The system was operated as follows: (1) Calibration of the pressure sensors. (2) Adjustment of alarm set points: low inlet pressure 3.0 Bars, high inlet pressure 3.5 Bars, differential pressure 0.3 Bars. (3) Washing of the system and the cartridges with deionized, distilled water (4) Fill-up of the reservoir with process solution; the solution is kept at 8-10°C by recirculating cold water (HAAKE, DC1-K20 refrigerated circulator) through the cooling coil. (5) Setting of the level switch at the desired concentration volume (1/4 to 1/5 of the initial volume). (6) Operation of the recirculation pump at 75 %. (7) Adjustment of the Back Pressure Valve to obtain a 3.0 Bar inlet pressure. If

necessary, back pressure was reduced during operation.

Once the fermentation broth was concentrated to the desired volume, the solution was diafiltered in order to remove low molecular weight solutes (Salts, sugars, etc.).

The system configuration allows the operation in the "pumped diafiltration with automatic safety stop" mode. The dialysate (five volumes of deionized water) was transferred by the secondary pump in steps as directed by the level switch. Once the dialysate supply is exhausted, the system and the secondary pump will shut off automatically.

The diafiltered solution is drained from the system, sterilized by filtration (Stericup, 0.22  $\mu$ m, Millipore) and stored at 4°C.

#### D.2. Purification of recombinant thaumatin to homogeneity

Recombinant thaumatin was purified to homogeneity using a four step purification scheme that is detailed in Table 4. The starting point for the particular purification protocol that is described here are 500 ml of fermentation broth obtained from the growth of strain TGDTh-4, with thaumatin present at a concentration of 50 mg/l.

Proteins from this broth were precipitated with ammonium sulfate (20-50% range). The precipitate was then re-suspended in 25 mM phosphate buffer, pH 7.0.

This mix was then passed through a Sephadex G-25 column (for desalting purposes) and eluted with the same buffer. Finally the sample was loaded onto a CM-Sephadex column at a flux of 0.5 ml/minute. The column was washed with 25 mM phosphate buffer, pH 7.0 in order to eliminate proteins in the flow-through fraction. Thaumatin was eluted with a NaCl linear gradient (0-400 mM). Thaumatin is eluted from this column in

almost pure form as detected by Coomassie Blue staining.

-----  
Table 4: Purification of thaumatin from the fermentation broth  
5 from growing strain TGDTh-4 in MDFA medium

-----

10	SAMPLE	VOLUME (ml)	CONC. (mg/l)	TOTAL (mg)	YIELD (%)
	Broth	500	50	25	100
	Ammonium sulfate	11	1745	19.2	76.8
15	Sephadex G-25	30	596	17.9	71.6
	CM-Sephadex	24	704	16.9	67.6

-----

20

While the foregoing illustrative examples are directed to the production of recombinant thaumatin, the production of any other recombinant protein by means of the new methodology provided in the present invention, particularly  
25 the new promoter and DNA constructions disclosed herein, is also encompassed by the present invention.

PCT/EP 99/02243

5 June 2000  
90/e/g/14

1

## CLAIMS

1. A promoter for the expression of recombinant proteins in filamentous fungi that comprises a nucleotide sequence - or a complementary strand thereof - selected from the group consisting of: (a) the nucleotide sequence numbered 1-740 in the enclosed SEQ ID No. 1; and a nucleotide sequence that hybridizes under stringent conditions to that defined in (a), with the proviso, that the sequence is not the promoter of the *gdh* gene from Aspergillus nidulans.
2. A promoter according to claim 1 which has the sequence of nucleotides numbered 1-740 in SEQ ID No. 1 or its complementary strand.
3. Isolated promoter of a glutamate dehydrogenase gene from a fungus of the genus Aspergillus with the proviso, that the sequence is not the promoter of the *gdh* gene from Aspergillus nidulans.
4. Isolated promoter according to claim 3 wherein the fungus is Aspergillus awamori or Aspergillus niger.
5. Isolated promoter according to claim 4 wherein the fungus is Aspergillus awamori.
6. A purified and isolated DNA sequence that encodes a glutamate dehydrogenase protein and that comprises a nucleotide sequence - or a complementary strand thereof - selected from the group consisting of: (a) the nucleotide sequence numbered 741-2245 in the enclosed SEQ ID No. 1; and (b) a nucleotide sequence that hybridizes under stringent conditions to that defined in (a), with the

05.05.00

2

proviso, that the sequence is not the *gdh* gene from *Aspergillus nidulans*.

7. A DNA sequence according to claim 6 which has the sequence of nucleotides numbered 741-2242 in SEQ ID No. 1, or its complementary strand.

8. An isolated DNA sequence encoding a glutamate dehydrogenase from a fungus of the genus *Aspergillus*, with the proviso, that the sequence is not the *gdh* gene from *Aspergillus nidulans*.

9. An isolated DNA sequence according to claim 8 wherein the fungus is *Aspergillus awamori* or *Aspergillus niger*.

10. An isolated DNA sequence according to claim 9 wherein the fungus is *Aspergillus awamori*.

11. The protein encoded by any of the DNA sequences according to claim 6.

12. The protein which has the amino acid sequence in SEQ ID No. 2.

13. An isolated glutamate dehydrogenase from a fungus of the genus *Aspergillus* with the proviso, that the glutamate dehydrogenase is not the glutamate dehydrogenase from *Aspergillus nidulans*.

14. An isolated glutamate dehydrogenase according to claim 13, wherein the fungus is *Aspergillus awamori* or *Aspergillus niger*.



H 05 06 00

3

15. An isolated glutamate dehydrogenase according to claim 14, wherein the fungus is Aspergillus awamori.

5 16. Use of a promoter from a glutamate dehydrogenase gene from a fungus of the genus Aspergillus for the expression of recombinant proteins in filamentous fungi.

10 17. Use according to claim 16, wherein the promoter is a promoter according to any one of claims 1 to 5.

18. A DNA construction that comprises: a) a promoter from a glutamate dehydrogenase gene from a fungus of the genus Aspergillus; b) a DNA sequence encoding a protein normally expressed from a filamentous fungus or a portion thereof; c) 15 a DNA sequence encoding a cleavable linker peptide; and d) a DNA sequence encoding a desired protein.

20 19. A DNA construction according to claim 18, wherein the promoter under a) is a promoter according to any one of claims 1 to 5.

20. A DNA construction according to claim 18, wherein the DNA sequence under b) encodes a protein or portion thereof selected from the group consisting of: i) glucoamylase from 25 Aspergillus awamori, Aspergillus niger, Aspergillus oryzae or Aspergillus sojae; ii) B2 from Acremonium chrysogenum; and iii) a glutamate dehydrogenase from a filamentous fungus.

30 21. A DNA construction according to claim 20, wherein the DNA sequence under b) encodes glucoamylase from Aspergillus awamori, Aspergillus niger, Aspergillus oryzae or Aspergillus sojae or a portion thereof.

NO. 05.05.00

4

22. A DNA construction according to claim 20, wherein the DNA sequence under b) encodes the protein B2 from Acremonium chrysogenum or a portion thereof.

5 23. A DNA construction according to claim 20, wherein the DNA sequence under b) encodes a glutamate dehydrogenase from a filamentous fungus or a portion thereof.

10 24. A DNA construction according to claim 18, wherein the DNA sequence under c) contains a KEX2 processing sequence.

25. A DNA construction according to any one of claims 18 to 24, wherein the DNA sequence under d) encodes thaumatin.

15 26. A DNA construction according to claim 25, wherein the DNA sequence under d) is the thaumatin II synthetic gene from plasmid pThIX disclosed in EP 684312.

20 27. A DNA construction comprising a gdh promoter from a fungus of the genus Aspergillus operatively linked to a DNA sequence encoding a recombinant protein.

25 28. A DNA construction according to claim 27, wherein the promoter is a promoter according to any one of claims 1 to 5.

30 29. A filamentous fungus culture capable of producing a recombinant protein which has been transformed with a plasmid containing a DNA construction according to any one of claims 18 to 28.

30. A culture according to claim 29, wherein the filamentous fungus is a fungus from the genus Aspergillus.

1405.05.00

5.

31. A culture according to claim 29, wherein the filamentous fungus is selected from the group consisting of Aspergillus awamori, Aspergillus niger, Aspergillus oryzae, Aspergillus nidulans and Aspergillus sojae.

5

32. A culture according to claim 29, wherein the plasmid contains a DNA construction according to any one of claims 25 or 26.

- 10 33. A process for producing a recombinant protein in a filamentous fungus comprising the following steps:
- a) preparation of an expression plasmid containing a DNA construct according to any of claims 18 to 28;
  - b) transformation of a strain of filamentous fungus with
  - 15 said expression plasmid;
  - c) culture of the transformed strain under appropriate nutrient conditions to produce the desired protein, either intracellularly, extracellularly or in both ways simultaneously; and
  - 20 d) depending on the case, separation and purification of the desired protein from the fermentation broth.

34. A process according to claim 33, wherein the recombinant protein is thaumatin and the expression plasmid contains a
- 25 DNA construction according to claims 25 or 26.

35. Use of a DNA sequence derived from a nucleotide sequence according to claims 1 to 6 as a probe for the identification and isolation of a glutamate dehydrogenase gene and/or a
- 30 promoter sequence of a glutamate dehydrogenase gene.

## SEQUENCE LISTING

SEQ ID 1. Nucleotide sequence of 2570 bp of a DNA fragment present in plasmid pBSGh, as well as the 5' end from plasmid pB1.7, which contains the *gdhA* gene of *A. awamori*. The numbers to the right indicate the numbering of the sequence. The promoter region of the *gdhA* gene of *A. awamori* precedes the initiating ATG codon at position 741 in the sequence. The initiation of transcription is at T of position -86 with respect to the translation initiation triplet (position 655 in the sequence). The part of the gene encoding the protein begins at position 741. The numbers underneath the amino acids refer to their numbering. There are a total of 460 amino acids. The two introns present are also shown.

20	TCTAGATTGC GAGGCGGAT TGCCTATCCT TAGTAGGACT CCTAATGGA TTCCGAGCAA	60
	GAAAGACTG TTTGGCGTGT ACCAATGGCT CATAGTACCA GCAGAGAGAG AATTTTCTCT	120
	CTGCTTCGA GAAAGCAATC AAAAAAAT CCTATCCTAC CCTACCTAC CTAATACTT	180
25	CCATTGOCAC CCGATTCTC CCGATAGTAG AGGCGGOGAC TGCATTGCG CGGCGGGGCC	240
	AGCGATTCC CGCGATAGA TACGGGCGAG ATTCTGTGAC CTCAACTAT CGACTAACAG	300
	CCGAACCTC GCGGCGCAC GCGAAACCG CCGCGGAGC CGGCTCAT TGCCTTTTGG	360
30	CGGTGCGAG AANTGCGGCC TCGAGCGGAG ACTCCCTAGT GTGGTCTGTG TTGCTCTGT	420
	CGTCTGTATA GTACTAGT TACTAGTCTA CTACTGTACA GTGGATGCC TCGGGGGGGS	480
35	ACTTTATCTC CGACTCGGC GTTCTCTCTC CCTATATCCA CTCTACCTC TTCTCTCTCT	540
	TCTGTCTTTC TCCCGCTCT CGGCCCTCCC CTCTCGAAA ACATAAATCG GCGTTTCCCT	600
40	CTGGCCACTC TCTCTCTTT CTCTCTCTCC TTCTCTTTC TTCTCGAC TACTCTCTT	660
	TCTTCTCTCT TTCTCTATA TTCTGTCTT CCTAGATACC CCAGTTAAAA AAGTCTCTCT	720
	AATCAATCTC CCCTTCGAGA ATG TCT AAC CTT CCT CAC GAG CCC GAG TTC	770
45	Met Ser Asn Leu Pro His Glu Pro Glu Phe	10
	GAG CAG GCC TAC AAG GGTATGTTCC ATTCCCTCC CGAATATGAT GATGGAAAA	825
	Glu Gln Ala Tyr Lys	15
50	AAATCTAAC AACATCTCT TACA GAG CTT GCC TCG ACC CTT GAG AAC TCC	876
	Glu Leu Ala Ser Thr Leu Glu Asn Ser	20
55	ACC CTC TTC CAG AAG AAC CCC GAA TAC CGC AAG GCC CTT GCT GTC GTC	924
	Thr Leu Phe Gln Lys Asn Pro Glu Tyr Arg Lys Ala Leu Ala Val Val	25 30 35 40

	TCC GTC CCC GAG CGT GTC ATC CAG TTC CGT GTC GTC TGG GAG GAT GAT Ser Val Pro Glu Arg Val Ile Gln Phe Arg Val Val Tsp Glu Asp Asp	972
5	GCC GGC AAC CTC GAG GTC AAC CGC GGT TTC CGT GTC CAG TTC AAC AGC Ala Gly Asn Val Gln Val Asn Arg Val Arg Val Gln Phe Asn Ser 45 50 55	1020
10	GCC CTC GGT CCC TAC AAG GGT GGT CTT CGT TTC CAC CCC TCC GTC AAC Ala Leu Gly Pro Tyr Lys Gly Gly Leu Arg Phe His Pro Ser Val Asn 75 80 85	1068
15	TTC TCC ATC CTC AAG TTC CTT GGT TTC GAG CAG ATC TTC AAG AAT GCT Leu Ser Ile Leu Lys Phe Leu Gly Phe Glu Gln Ile Phe Lys Asn Ala 90 95 100	1116
20	CTC ACT GGC CTG AAC ATG GGT GGT AAG GGT GGT TCC GAC TTC GAC Leu Thr Gly Leu Asn Met Gly Gly Gly Lys Gly Ser Asp Phe Asp 105 110 115 120	1164
25	CCC AAG GGC AAG TCC GAC AAC CAG ATC CGT CGC TTC TGT GTT TCC TTC Pro Lys Gly Lys Ser Asp Asn Glu Ile Arg Arg Phe Cys Val Ser Phe 125 130 135	1212
30	ATG ACC GAG CTC TGC AAC CAG ATC ATC GGT GCC GAC ACT GAT GTT CCC GCT Met Thr Glu Leu Cys Lys His Ile Gly Ala Asp Thr Asp Val Pro Ala 140 145 150	1260
35	GGT GAC ATC GGT GTC AAC GGT CGT GAG GTC GGT TTC CTC TTC GGC CAG Gly Arg Ile Gly Val Thr Gly Arg Glu Val Gly Phe Leu Phe Gly Gln 155 160 165	1308
40	TAC CGC AAG ATC CGC AAC CAG TGC GAG GGT GTT CTC ACC GGT AAG GGT Tyr Arg Lys Ile Arg Asn Gln Tsp Glu Gly Val Leu Thr Gly Lys Gly 170 175 180	1356
45	GCC AGC TGG GGT GGT TCC CTC ATC CGC CCT GAG GCC ACC GGT TAC GGT Gly Ser Tsp Gly Gly Ser Leu Ile Arg Pro Glu Ala Thr Gly Tyr Gly 185 190 195 200	1404
50	GGT GTC TAC GTATGCAAT TCGCTCTT ATGATTCT ATGTATACA Val Val Tyr	1453
55	CGGACTACG CGGTACAG TAC GTC CAG CAC ATG ATT GCT CAC GCC ACC AAC Tyr Val Glu His Met Ile Ala His Ala Thr Asn 205 210	1504
60	GCC CAG GAG TCC TTC AAG GGC AAG CGC GTT GCC ATC TCC GGT TCC GGT Gly Gln Glu Ser Phe Lys Gly Lys Arg Val Ala Ile Ser Gly Ser Gly 215 220 225 230	1552
65	Asn GTT GCC CAG TAC GCC CCC ATC AAG GTC ATT GAG CTC GGC GGT TCC Ala Val Ala Gln Tyr Ala Ala Leu Lys Val Ile Glu Leu Gly Ser 235 240 245	1600
70	GTC GTC TCC CTG AGC GAC ACG CAG GGC TCC CTC ATC ATC AAC GGC GAG Val Val Ser Leu Ser Asp Thr Gln Gly Ser Leu Ile Ile Asn Gly Glu 250 255 260	1648
75	GGT AGC TTC ACC CCC GAG GAG ATC GAG CTC ATC GCT CAG ACC AAG GCT Gly Ser Phe Thr Pro Glu Glu Ile Glu Leu Ile Ala Gln Thr Lys Val 265 270 275	1696
80	GAG CGC AAC CAG CTC GCC AGC ATC GTC GGT GGT GCT CCC TTC AGC GAC Glu Arg Asn Glu Leu Ala Ser Ile Val Gly Ala Ala Pro Phe Ser Asp 280 285 290	1744
85	GCC AAC AAG TTC AAG TAC ATT GGT GGT GCC CGC CCC TGG GTT CAG GTC Ala Asn Lys Phe Lys Tyr Ile Ala Gly Ala Arg Pro Trp Val His Val 295 300 305 310	1792

	GGC AAG GTC GAC GTC GCT CTC CCC TCC GGT ACC CAG AAC GAA GTT TCC Gly Lys Val Asp Val Ala Leu Pro Ser Ala Thr Gln Asn Glu Val Ser 315 320 325	1840
5	GGC GAG GAG GCC CAG GTC CTC ATC AAC GCT GGC TGC AAG TTC ATC GCC Gly Glu Glu Ala Gln Val Leu Ile Asn Ala Gly Cys Lys Phe Ile Ala 330 335 340	1888
10	GAG GGT TCC AAC ATG GGT TGC ACC CAG GAG GCC ATC GAC ACC TTC GAG Glu Gly Ser Asn Met Gly Cys Thr Gln Glu Ala Ile Asp Thr Phe Glu 345 350 355	1936
15	GCC CAC CGT ACC GCC AAC GCT GGC GCG GCT GCC ATC TGG TAC GCC CCC Ala His Arg Thr Ala Asn Ala Gly Ala Ala Ala Ile Trp Tyr Ala Pro 360 365 370	1984
	GGT AAG GCC GCC AAC GCC GGT GGT GTC GCT GTC TCC GGT CTG GAG ATG Gly Lys Ala Ala Asn Ala Gly Gly Val Ala Val Ser Gly Leu Glu Met 375 380 385 390	2032
20	GCT CAG AAC TCT GCC CGC CTC AGC TGG ACT TCT GAG GAG GTT GAT GCC Ala Gln Asn Ser Ala Arg Leu Ser Trp Thr Ser Glu Glu Val Asp Ala 395 400 405	2080
25	CGT CTT AAG GAC ATC ATG CGC GAC TGC TTC AAG AAC GGT CTT GAG ACT Arg Leu Lys Asp Ile Met Arg Asp Cys Phe Lys Asn Gly Leu Glu Thr 410 415 420	2128
30	GCT CAG GAG TAC GCC ACC CCC GCT GAG GGT GTC CTG CCT TCC CTG GTG Ala Gln Glu Tyr Ala Thr Pro Ala Glu Gly Val Leu Pro Ser Leu Val 425 430 435	2176
35	ACC GGA TCC AAC ATT GCC GGT TTC ACC AAG GTG GCT GCC GCC ATG AAG Thr Gly Ser Asn Ile Ala Gly Phe Thr Lys Val Ala Ala Met Lys 440 445 450	2224
	GAC CAG GGT GAC TGG TGG TAAATGCGGA AACCCGAAA CCCCCGGGC Asp Gln Gly Asp Trp Trp 455 460	2272
40	TTATGTCATG ACGATTATGT AGTTTGATGT TCCCTTTCAG CGCGGATGGA TAGAGGGGCC GGGTGTTTCT TGCTAGTTTA GATGGATGCA TAATGATATC CTTTTCCTAA TCCTCAATT 465 470 475 480 485 490	2320
45	CTGTAAATTT GTTGTAACAA TAGTAGATAA TACAACTGTA GTCACTACC CTGCACTTT CACTATTTC AGATGCATTC ATCTCTATTC CGAGCAGATC CAGAAACCCA TGGACGCGA 495 500 505 510 515 520	2368
50	GTTCACAGT ACTTAGGCTG TTAATCTCCC TCTATGGCAT CTTAAACAAC TATCTAGA 525 530 535 540 545	2416

SEQ ID 2. Amino acid sequence of the glutamate dehydrogenase A (gdh A) protein from Aspergillus awamori as deduced from the nucleotide sequence in SEQ ID 1.

55

Met Ser Asn Leu Pro His Glu Pro Glu Phe Glu Gln Ala Tyr Lys Glu  
1 5 10 15

60. Leu Ala Ser Thr Leu Glu Asn Ser Thr Leu Phe Gln Lys Asn Pro Glu  
20 25 30

Tyr Arg Lys Ala Leu Ala Val Val Ser Val Pro Glu Arg Val Ile Gln  
35 40 45

65

	Phe Arg Val Val Trp Glu Asp Asp Ala Gly Asn Val Gln Val Asn Arg	50	55	60	
5	Gly Phe Arg Val Gln Phe Asn Ser Ala Leu Gly Pro Tyr Lys Gly Gly	65	70	75	80
	Leu Arg Phe His Pro Ser Val Asn Leu Ser Ile Leu Lys Phe Leu Gly	85	90	95	
10	Phe Glu Gln Ile Phe Lys Asn Ala Leu Thr Gly Leu Asn Met Gly Gly	100	105	110	
	Gly Lys Gly Gly Ser Asp Phe Asp Pro Lys Gly Lys Ser Asp Asn Glu	115	120	125	
15	Ile Arg Arg Phe Cys Val Ser Phe Met Thr Glu Leu Cys Lys His Ile	130	135	140	
20	Gly Ala Asp Thr Asp Val Pro Ala Gly Asp Ile Gly Val Thr Gly Arg	145	150	155	160
	Glu Val Gly Phe Leu Phe Gly Gln Tyr Arg Lys Ile Arg Asn Gln Trp	165	170	175	
25	Glu Gly Val Leu Thr Gly Lys Gly Gly Ser Trp Gly Gly Ser Leu Ile	180	185	190	
	Arg Pro Glu Ala Thr Gly Tyr Gly Val Val Tyr Tyr Val Glu His Met	195	200	205	
30	Ile Ala His Ala Thr Asn Gly Gln Glu Ser Phe Lys Gly Lys Arg Val	210	215	220	
35	Ala Ile Ser Gly Ser Gly Asn Val Ala Gln Tyr Ala Ala Leu Lys Val	225	230	235	240
	Ile Glu Leu Gly Gly Ser Val Val Ser Leu Ser Asp Thr Gln Gly Ser	245	250	255	
40	Leu Ile Ile Asn Gly Glu Gly Ser Phe Thr Pro Glu Glu Ile Glu Leu	260	265	270	
	Ile Ala Gln Thr Lys Val Glu Arg Asn Glu Leu Ala Ser Ile Val Gly	275	280	285	
45	Ala Ala Pro Phe Ser Asp Ala Asn Lys Phe Lys Tyr Ile Ala Gly Ala	290	295	300	
50	Arg Pro Trp Val His Val Gly Lys Val Asp Val Ala Leu Pro Ser Ala	305	310	315	320
	Thr Gln Asn Glu Val Ser Gly Glu Glu Ala Gln Val Leu Ile Asn Ala	325	330	335	
55	Gly Cys Lys Phe Ile Ala Glu Gly Ser Asn Met Gly Cys Thr Gln Glu	340	345	350	
	Ala Ile Asp Thr Phe Glu Ala His Arg Thr Ala Asn Ala Gly Ala Ala	355	360	365	

Ala Ile Trp Tyr Ala Pro Gly Lys Ala Ala Asn Ala Gly Gly Val Ala  
 370 375 380

5 Val Ser Gly Leu Glu Met Ala Gln Asn Ser Ala Arg Leu Ser Trp Thr  
 385 390 395 400

Ser Glu Glu Val Asp Ala Arg Leu Lys Asp Ile Met Arg Asp Cys Phe  
 405 410 415

10 Lys Asn Gly Leu Glu Thr Ala Gln Glu Tyr Ala Thr Pro Ala Glu Gly  
 420 425 430

Val Leu Pro Ser Leu Val Thr Gly Ser Asn Ile Ala Gly Phe Thr Lys  
 435 440 445

15 Val Ala Ala Ala Met Lys Asp Gln Gly Asp Trp Trp  
 450 455 460

09647543-100200



Sequence Listings  
Rec'd on 14.9.99

## SEQUENCE LISTING

<110> URQUIMA, S.A.

<120> Promotor and constructions for expression of recombinant proteins in filamentous fungi

<130> Thaumatin 2

<140> PCT/EP 99/02243

<141> 1999-04-01

<150> ES 9800699

<151> 1998-04-02

<160> 13

<170> PatentIn Ver. 2.1

<210> 1

<211> 2570

<212> DNA

<213> Aspergillus awamorii

<220>

<221> intron

<222> (785)..(850)

<220>

<221> intron

<222> (1414)..(1471)

<220>

<221> CDS

<222> (741)..(785)

<220>

<221> CDS

<222> (850)..(1413)

<220>

<221> CDS

<222> (1472)..(2242)

<400> 1

tctagattgc gacggcggtat tgcttatcct tagtaggact ccctaattgga ttccgagcaa 60

gaaaagactg tttggcggtg accaatggct catagtagca gcaagagaag aattttctct 120

ctcgcttcga gaaagcaatc aaaaaaaaaa cctatcctac cctaccctac cctaatactt 180

ccattgccac cggattcctc cggatagtag agcggggcgac tgcattttgg cgggcgggcc 240

agcggatttc cgccgataga taacggggcag attctgtgac ctcaaactat cgactaacag 300

cccgaacttc gggcgccacc gccaaacccg ccccgggaagc cggcctcatt tgccgtttgg 360

gcgtgccagg aaatgccgcc tgcagcggag actccctagt gtgggtctgtg ttgcctgtgt 420

cgtctgtgta gtatactagt tactagtcta ctactgtaca gtggatggcc tgaggggggg 480

09/647543-100200

acttttatgtc	cgactccggc	tggtttctctc	ctcttatcca	ctctaccctc	tctccctctct	540
tctgtgttttc	tccccgctct	cgccccctcc	ctctctgaaa	acataaatgc	gcctttcccc	600
ctcgccatct	tctttcttct	ctccctctcc	ttttcttttc	ttcttcagac	tactttctct	660
tctttctatct	ttctcttata	ttctgttttt	cctagatacc	ccagttaaaa	aagtctcttc	720
aatcaatcct	ccccctcaga	atg tct aac ctt cct cac gag ccc gag ttc gag	Met Ser Asn Leu Pro His Glu Pro Glu Phe Glu			773
		1	5	10		
cag gcc tac aag	ggatgtttcc	attgccctc	cgaaattgat	gatggaaaaa		825
Gln Ala Tyr Lys						
	15					
aaattctaac	aacatctct	taca gag ctt gcc tcg acc ctt gag aac tcc	Glu Leu Ala Ser Thr Leu Glu Asn Ser			876
			20			
acc ctg ttc	cag aag aac ccc gaa tac cgc aag gcc ctt gct gtc gtc					924
Thr Leu Phe Gln Lys Asn Pro Glu Tyr Arg Lys Ala Leu Ala Val Val						
25	30		35		40	
tcc gtc ccc gag cgt gtc atc cag ttc cgt gtc gtc tgg gag gat gat						972
Ser Val Pro Glu Arg Val Ile Gln Phe Arg Val Val Trp Glu Asp Asp						
	45		50		55	
gcc ggc aac gtc cag gtc aac cgc ggt ttc cgt gtc cag ttc aac agc						1020
Ala Gly Asn Val Gln Val Asn Arg Gly Phe Arg Val Gln Phe Asn Ser						
	60		65		70	
gcc ctg ggt ccc tac aag ggt ggt ctt cgt ttc cac ccc tcc gtc aac						1068
Ala Leu Gly Pro Tyr Lys Gly Gly Leu Arg Phe His Pro Ser Val Asn						
	75		80		85	
ttg tcc atc ctg aag ttc ctt ggt ttc gag cag atc ttc aag aat gct						1116
Leu Ser Ile Leu Lys Phe Leu Gly Phe Glu Gln Ile Phe Lys Asn Ala						
	90		95		100	
ctc act ggc ctg aac atg ggt ggt ggt aag ggt ggt tcc gac ttc gac						1164
Leu Thr Gly Leu Asn Met Gly Gly Gly Lys Gly Gly Ser Asp Phe Asp						
105	110		115		120	
ccc aag ggc aag tcc gac aac gag atc cgt cgc ttc tgt gtt tcc ttc						1212
Pro Lys Gly Lys Ser Asp Asn Glu Ile Arg Arg Phe Cys Val Ser Phe						
	125		130		135	
atg acc gag ctg tgc aag cac atc ggt gcc gac act gat gtt ccc gct						1260
Met Thr Glu Leu Lys His Ile Gly Ala Asp Thr Asp Val Pro Ala						
	140		145		150	
ggt gac atc ggt gtc acc ggt cgt gag gtc ggt ttc ctg ttc gcc cag						1308
Gly Asp Ile Gly Val Thr Gly Arg Glu Val Gly Phe Leu Phe Gly Gln						
	155		160		165	
tac cgc aag atc cgc aac cag tgg gag ggt gtt ctg acc ggt aag ggt						1356
Tyr Arg Lys Ile Arg Asn Gln Trp Glu Gly Val Leu Thr Gly Lys Gly						
	170		175		180	

ggc agc tgg ggt ggt tcc ctc atc cgc cct gag gcc acc ggt tac ggt 1404  
 Gly Ser Trp Gly Gly Ser Leu Ile Arg Pro Glu Ala Thr Gly Tyr Gly  
 185 190 195 200  
 gtt gtc tac gtatgtcaat tcctcttctt atgattatct atgtataaca 1453  
 Val Val Tyr  
 gcgactaacg cgtaacag tac gtc gag cac atg att gct cac gcc acc aac 1504  
 Tyr Val Glu His Met Ile Ala His Ala Thr Asn  
 205 210  
 ggc cag gag tcc ttc aag ggc aag cgc gtt gcc atc tcc ggt tcc ggt 1552  
 Gly Gln Glu Ser Phe Lys Gly Lys Arg Val Ala Ile Ser Gly Ser Gly  
 215 220 225 230  
 aac gtt gcc cag tac gcc gcc ctc aag gtc att gag ctc ggc ggt tcc 1600  
 Asn Val Ala Gln Tyr Ala Ala Leu Lys Val Ile Glu Leu Gly Gly Ser  
 235 240 245  
 gtc gtc tcc ctg agc gac acg cag gcc tcc ctc atc atc aac ggc gag 1648  
 Val Val Ser Leu Ser Asp Thr Gln Gly Ser Leu Ile Ile Asn Gly Glu  
 250 255 260  
 ggt agc ttc acc ccc gag gag atc gag ctc atc gct cag acc aag gtc 1696  
 Gly Ser Phe Thr Pro Glu Glu Ile Glu Leu Ile Ala Gln Thr Lys Val  
 265 270 275  
 gag cgc aac gag ctc gcc agc atc gtc ggt gct gct ccc ttc agc gac 1744  
 Glu Arg Asn Glu Leu Ala Ser Ile Val Gly Ala Ala Pro Phe Ser Asp  
 280 285 290  
 gcc aac aag ttc aag tac att gct ggt gcc cgc ccc tgg gtt cac gtc 1792  
 Ala Asn Lys Phe Lys Tyr Ile Ala Gly Ala Arg Pro Trp Val His Val  
 295 300 305 310  
 ggc aag gtc gac gtc gct ctc ccc tcc gct acc cag aac gaa gtt tcc 1840  
 Gly Lys Val Asp Val Ala Leu Pro Ser Ala Thr Gln Asn Glu Val Ser  
 315 320 325  
 ggc gag gag gcc cag gtc ctc atc aac gct ggc tgc aag ttc atc gcc 1888  
 Gly Glu Glu Ala Gln Val Leu Ile Asn Ala Gly Cys Lys Phe Ile Ala  
 330 335 340  
 gag ggt tcc aac atg ggt tgc acc cag gag gcc atc gac acc ttc gag 1936  
 Glu Gly Ser Asn Met Gly Cys Thr Gln Glu Ala Ile Asp Thr Phe Glu  
 345 350 355  
 gcc cac cgt acc gcc aac gct ggc gcg gct gcc atc tgg tac gcc ccc 1984  
 Ala His Arg Thr Ala Asn Ala Gly Ala Ala Ala Ile Trp Tyr Ala Pro  
 360 365 370  
 ggt aag gcc gcc aac gcc ggt ggt gtc gct gtc tcc ggt ctg gag atg 2032  
 Gly Lys Ala Ala Asn Ala Gly Gly Val Ala Val Ser Gly Leu Glu Met  
 375 380 385 390  
 gct cag aac tct gcc cgc ctc agc tgg act tct gag gag gtt gat gcc 2080  
 Ala Gln Asn Ser Ala Arg Leu Ser Trp Thr Ser Glu Glu Val Asp Ala  
 395 400 405

002001-2152166

cgt ctt aag gac atc atg cgc gac tgc ttc aag aac ggt ctt gag act 2128  
 Arg Leu Lys Asp Ile Met Arg Asp Cys Phe Lys Asn Gly Leu Glu Thr  
 410 415 420

gct cag gag tac gcc acc ccc gct gag ggt gtc ctg cct tcc ctg gtg 2176  
 Ala Gln Glu Tyr Ala Thr Pro Ala Glu Gly Val Leu Pro Ser Leu Val  
 425 430 435

acc gga tcc aac att gcc ggt ttc acc aag gtg gct gcc gcc atg aag 2224  
 Thr Gly Ser Asn Ile Ala Gly Phe Thr Lys Val Ala Ala Met Lys  
 440 445 450

gac cag ggt gac tgg tgg taaatgcgga aagccgcaaa cccccgcggc 2272  
 Asp Gln Gly Asp Trp,Trp  
 455 460

ttatgtcatg acgattatgt agtttgatgt tccctttcag cgcggatgga tagaggcgcc 2332

ggtgttttct tgctagttaa gatggatgca taatgatatc tttttcttaa tcctcaaatt 2392

cttgtaattt gttgtatcaa tagtagataa tacaactgta gtcaactacc cttgcatctt 2452

cactatttgc agatgcattc atctctattc cgagcacatg cacaacacca tgggaccgca 2512

gttcactagt acttagcctg ttatcttccc tctatcgcat cttaaacaac tatctaga 2570

<210> 2

<211> 460

<212> PRT

<213> Aspergillus awamorii

<400> 2

Met Ser Asn Leu Pro His Glu Pro Glu Phe Glu Gln Ala Tyr Lys Glu  
 1 5 10 15

Leu Ala Ser Thr Leu Glu Asn Ser Thr Leu Phe Gln Lys Asn Pro Glu  
 20 25 30

Tyr Arg Lys Ala Leu Ala Val Val Ser Val Pro Glu Arg Val Ile Gln  
 35 40 45

Phe Arg Val Val Trp Glu Asp Ala Gly Asn Val Gln Val Asn Arg  
 50 55 60

Gly Phe Arg Val Gln Phe Asn Ser Ala Leu Gly Pro Tyr Lys Gly Gly  
 65 70 75 80

Leu Arg Phe His Pro Ser Val Asn Leu Ser Ile Leu Lys Phe Leu Gly  
 85 90 95

Phe Glu Gln Ile Phe Lys Asn Ala Leu Thr Gly Leu Asn Met Gly Gly  
 100 105 110

Gly Lys Gly Gly Ser Asp Phe Asp Pro Lys Gly Lys Ser Asp Asn Glu  
 115 120 125

Ile Arg Arg Phe Cys Val Ser Phe Met Thr Glu Leu Cys Lys His Ile  
 130 135 140

00647543-100200

Gly Ala Asp Thr Asp Val Pro Ala Gly Asp Ile Gly Val Thr Gly Arg  
145 150 155 160

Glu Val Gly Phe Leu Phe Gly Gln Tyr Arg Lys Ile Arg Asn Gln Trp  
165 170 175

Glu Gly Val Leu Thr Gly Lys Gly Gly Ser Trp Gly Gly Ser Leu Ile  
180 185 190

Arg Pro Glu Ala Thr Gly Tyr Gly Val Val Tyr Tyr Val Glu His Met  
195 200 205

Ile Ala His Ala Thr Asn Gly Gln Glu Ser Phe Lys Gly Lys Arg Val  
210 215 220

Ala Ile Ser Gly Ser Gly Asn Val Ala Gln Tyr Ala Ala Leu Lys Val  
225 230 235 240

Ile Glu Leu Gly Gly Ser Val Val Ser Leu Ser Asp Thr Gln Gly Ser  
245 250 255

Leu Ile Ile Asn Gly Glu Gly Ser Phe Thr Pro Glu Glu Ile Glu Leu  
260 265 270

Ile Ala Gln Thr Lys Val Glu Arg Asn Glu Leu Ala Ser Ile Val Gly  
275 280 285

Ala Ala Pro Phe Ser Asp Ala Asn Lys Phe Lys Tyr Ile Ala Gly Ala  
290 295 300

Arg Pro Trp Val His Val Gly Lys Val Asp Val Ala Leu Pro Ser Ala  
305 310 315 320

Thr Gln Asn Glu Val Ser Gly Glu Glu Ala Gln Val Leu Ile Asn Ala  
325 330 335

Gly Cys Lys Phe Ile Ala Glu Gly Ser Asn Met Gly Cys Thr Gln Glu  
340 345 350

Ala Ile Asp Thr Phe Glu Ala His Arg Thr Ala Asn Ala Gly Ala Ala  
355 360 365

Ala Ile Trp Tyr Ala Pro Gly Lys Ala Ala Asn Ala Gly Gly Val Ala  
370 375 380

Val Ser Gly Leu Glu Met Ala Gln Asn Ser Ala Arg Leu Ser Trp Thr  
385 390 395 400

Ser Glu Glu Val Asp Ala Arg Leu Lys Asp Ile Met Arg Asp Cys Phe  
405 410 415

Lys Asn Gly Leu Glu Thr Ala Gln Glu Tyr Ala Thr Pro Ala Glu Gly  
420 425 430

Val Leu Pro Ser Leu Val Thr Gly Ser Asn Ile Ala Gly Phe Thr Lys  
435 440 445

Val Ala Ala Ala Met Lys Asp Gln Gly Asp Trp Trp  
450 455 460

00647543-100200

<210> 3  
 <211> 33  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:  
 Oligonucleotide ThS1

<400> 3  
 cgaatgaaaa ggaaaaggat ggccaccttc gag

33

<210> 4  
 <211> 18  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:Oligonucleotide  
 ThS2

<400> 4  
 ttattaggcg gtggggca

18

<210> 5  
 <211> 18  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:  
 Oligonucleotide IA

<400> 5  
 atgtctaacc ttcctcac

18

<210> 6  
 <211> 18  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:  
 Oligonucleotide IB

<400> 6  
 acccttacca ccacccat

18

<210> 7  
 <211> 18  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:  
 Oligonucleotide IIA

002001-452490

<400> 7  
 cgcttctgtg tttccttc 18

<210> 8  
 <211> 18  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:Oligonucleotide  
 IIB

<400> 8  
 gtacttgaac ttgttggc 18

<210> 9  
 <211> 28  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:Oligonucleotide  
 gdh1

<400> 9  
 ttttgtcgac ttgcgacggc gtattgct 28

<210> 10  
 <211> 28  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:Oligonucleotide  
 gdh2

<400> 10  
 ttttccatgg tctgaagggg aggattga 28

<210> 11  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:  
 Oligonucleotide Pe

<400> 11  
 ggggttcttc tggaagaggg t 21

<210> 12  
 <211> 18  
 <212> DNA  
 <213> Artificial Sequence

002001 " 4+574960

<220>

<223> Description of Artificial Sequence:  
Oligonucleotide NTB2b

<400> 12

atgcgtgctg ctactctc

18

<210> 13

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:  
Oligonucleotide CTB2b

<400> 13

ctggccgttg ttgatgag

18

002001-34574900



1/18

Fig. 1A




Fig. 1B




Fig. 1C




Fig. 2




Fig. 3




Fig. 4A

Figure 1. The effect of the concentration of the *Agrobacterium* suspension on the transformation efficiency of *Agrobacterium* strains. The concentration of the *Agrobacterium* suspension was 10<sup>6</sup> cells/ml (A), 10<sup>7</sup> cells/ml (B), 10<sup>8</sup> cells/ml (C), and 10<sup>9</sup> cells/ml (D). The transformation efficiency was determined by the number of transformants per 10<sup>6</sup> cells of *Agrobacterium* suspension. The data are the mean ± SD of three independent experiments.

[illegible]

8/18

Fig. 5






Fig. 6

G A T C Pe



← *gdhA*

Fig. 7



11/18







Fig. 8


12/18

Fig. 9

A




B




13/18

Fig. 10A



14/18

Fig. 10B



15/18

Fig. 10C




Fig. 11A







Fig. 11B

pB2KThb1


pGPDTh

*Bam*HI  
*Klenow*  
*Hind*III*Dra*I-*Sac*I\*  
*Hind*IIIpGPTThb1  
7300 pb

18/18

Fig. 12

TB2b1-44 and TGDTh-4



**COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY**  
(Includes Reference to Provisional and PCT International Applications)

Attorney's Docket No.

031309-003

As a below named inventor, I hereby declare that:  
My residence, post office address and citizenship are as stated below next to my name;  
I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor  
(if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention  
entitled:

**PROMOTER AND CONSTRUCTIONS FOR EXPRESSION OF RECOMBINANT PROTEINS IN**

**FILAMENTOUS FUNGI**

the specification of which (check only one item below):

☐ is attached hereto.

☐ was filed as United States application

Number \_\_\_\_\_

on \_\_\_\_\_

and was amended

on \_\_\_\_\_ (if applicable).

☒ was filed as PCT international application

Number PCT/EP99/02243

on 1 April 1999

and was amended

on 5 June 2000 (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 (a)-(c) of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

**PRIOR FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. §119:**

COUNTRY (if PCT, indicate "PCT")	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 U.S.C. §119
Spain (ES)	98 00699	2 April 1998	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No

I hereby claim the benefit under Title 35, United States Code § 119(c) of any United States provisional application(s) listed below.

\_\_\_\_\_  
(Application Number)

\_\_\_\_\_  
(Filing Date)

\_\_\_\_\_  
(Application Number)

\_\_\_\_\_  
(Filing Date)




\* PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. §120:

(5/00)

**COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY (CONT'D)**  
(Includes Reference to Provisional and PCT International Applications)

Attorney's Docket No.

031309-003

FULL NAME OF SOLE OR FIRST INVENTOR Miguel Sibilana Barrios		SIGNATURE 	DATE 29/06/00
RESIDENCE C/ Níquel, 216-218, 4 <sup>a</sup> 2 <sup>a</sup> , ES-08013 Barcelona, Spain		CITIZENSHIP Spain <b>ESX</b>	
POST OFFICE ADDRESS			
C/ Níquel, 216-218, 4 <sup>a</sup> 2 <sup>a</sup> , ES-08013 Barcelona, Spain			
FULL NAME OF SECOND JOINT INVENTOR, IF ANY Francisco Javier Casanueva Mena		SIGNATURE	DATE
RESIDENCE		CITIZENSHIP	
C/ Menéndez Pidal, 4, 2 <sup>a</sup> A, ES-24195-Villaciampo de las Rozas (LEON), Spain		Spain	
POST OFFICE ADDRESS			
C/ Menéndez Pidal, 4, 2 <sup>a</sup> A, ES-24195-Villaciampo de las Rozas (LEON), Spain			
FULL NAME OF THIRD JOINT INVENTOR, IF ANY Francisco José Morales Laredo		SIGNATURE	DATE
RESIDENCE		CITIZENSHIP	
C/ Rejedorada, 7, ES-49800-Toro (ZAMORA), Spain		Spain	
POST OFFICE ADDRESS			
C/ Rejedorada, 7, ES-49800-Toro (ZAMORA), Spain			
FULL NAME OF FOURTH JOINT INVENTOR, IF ANY Juan Francisco Martín Martín		SIGNATURE	DATE
RESIDENCE		CITIZENSHIP	
Avenida de la Facultad, 13, 4 <sup>a</sup> A, ES-24004-León, Spain		Spain	
POST OFFICE ADDRESS			
Avenida de la Facultad, 13, 4 <sup>a</sup> A, ES-24004-León, Spain			
FULL NAME OF FIFTH JOINT INVENTOR, IF ANY Santiago Quiñero Martín		SIGNATURE	DATE
RESIDENCE		CITIZENSHIP	
C/ José Bergamín, 5, 3 <sup>a</sup> C, ES-24195-Villaciampo de las Rozas (LEON), Spain		Spain	
POST OFFICE ADDRESS			
C/ José Bergamín, 5, 3 <sup>a</sup> C, ES-24195-Villaciampo de las Rozas (LEON), Spain			
FULL NAME OF SIXTH JOINT INVENTOR, IF ANY María José Tijerubín Irujo		SIGNATURE	DATE
RESIDENCE		CITIZENSHIP	
C/ Estación, 32, 8 <sup>a</sup> B, ES-09200-Miranda de Ebro (BURGOS), Spain		Spain	
POST OFFICE ADDRESS			
C/ Estación, 32, 8 <sup>a</sup> B, ES-09200-Miranda de Ebro (BURGOS), Spain			
FULL NAME OF SEVENTH JOINT INVENTOR, IF ANY José Luis Del Río Pericacho		SIGNATURE 	DATE 28/07/2000
RESIDENCE		CITIZENSHIP	
C/ Suroeste Casulla, 118, 3 <sup>a</sup> 1 <sup>a</sup> , ES-08022-Barcelona, Spain		Spain <b>ESX</b>	
POST OFFICE ADDRESS			
C/ Suroeste Casulla, 118, 3 <sup>a</sup> 1 <sup>a</sup> , ES-08022-Barcelona, Spain			
FULL NAME OF EIGHTH JOINT INVENTOR, IF ANY Ignacio Luis Sanguinetti		SIGNATURE 	DATE 28/07/2000
RESIDENCE		CITIZENSHIP	
C/ Ricardo Calvo, 8-10, 2 <sup>a</sup> 1 <sup>a</sup> , ES-08022-Barcelona, Spain		Spain <b>ESX</b>	
POST OFFICE ADDRESS			
C/ Ricardo Calvo, 8-10, 2 <sup>a</sup> 1 <sup>a</sup> , ES-08022-Barcelona, Spain			

**COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY (CONT'D)**  
*(Includes Reference to Provisional and PCT International Applications)*

Attorney's Docket No.

001300 0002

FULL NAME OF SOLID OR FIRST INVENTOR		SIGNATURE	DATE
Hendi Systems, S.A. RESIDENCE			
C/ Nicolas, 210-218, 4 <sup>th</sup> A, ES-08013-Barcelona, Spain			CITIZENSHIP Spain
POST OFFICE ADDRESS			
C/ Nicolas, 210-218, 4 <sup>th</sup> A, ES-08013-Barcelona, Spain			
FULL NAME OF SECOND JOINT INVENTOR, IF ANY		SIGNATURE	DATE
Francisco Javier Casarino Blanco RESIDENCE			September 28 <sup>th</sup> 2000
C/ Mercedes Pidal, 4, 2 <sup>nd</sup> A, ES-24195-Villavieja de las Requejas (LEON), Spain			CITIZENSHIP Spain
POST OFFICE ADDRESS			ESX
C/ Mercedes Pidal, 4, 2 <sup>nd</sup> A, ES-24195-Villavieja de las Requejas (LEON), Spain			
FULL NAME OF THIRD JOINT INVENTOR, IF ANY		SIGNATURE	DATE
Francisco José Murdrijo Lopez RESIDENCE			September 29 <sup>th</sup> 2000
C/ Relatopada, 7, ES-49000-Toro (ZAMORA), Spain			CITIZENSHIP Spain
POST OFFICE ADDRESS			ESX
C/ Relatopada, 7, ES-49000-Toro (ZAMORA), Spain			
FULL NAME OF FOURTH JOINT INVENTOR, IF ANY		SIGNATURE	DATE
Joaquín Martínez Martín RESIDENCE			September 27 <sup>th</sup> 2000
Arreda de la Facultad, 11, 4 <sup>th</sup> A, ES-24004-León, Spain			CITIZENSHIP Spain
POST OFFICE ADDRESS			ESX
Arreda de la Facultad, 11, 4 <sup>th</sup> A, ES-24004-León, Spain			
FULL NAME OF FIFTH JOINT INVENTOR, IF ANY		SIGNATURE	DATE
Rafaela Guzmán Marín RESIDENCE			28.09.00
C/ José Bergamín, 3, 3 <sup>rd</sup> C, ES-24195-Villavieja de las Requejas (LEON), Spain			CITIZENSHIP Spain
POST OFFICE ADDRESS			ESX
C/ José Bergamín, 3, 3 <sup>rd</sup> C, ES-24195-Villavieja de las Requejas (LEON), Spain			
FULL NAME OF SIXTH JOINT INVENTOR, IF ANY		SIGNATURE	DATE
Marta José Hita-Ruiz Ibarra RESIDENCE			29.09.00
C/ Elencio, 32, 4 <sup>th</sup> B, ES-00930-Miranda de Ebro (BURGOS), Spain			CITIZENSHIP Spain
POST OFFICE ADDRESS			ESX
C/ Elencio, 32, 4 <sup>th</sup> B, ES-00930-Miranda de Ebro (BURGOS), Spain			
FULL NAME OF SEVENTH JOINT INVENTOR, IF ANY		SIGNATURE	DATE
José Luis Del Río Peruchón RESIDENCE			
C/ Soleracast, 118, 2 <sup>nd</sup> A, ES-08022-Barcelona, Spain			CITIZENSHIP Spain
POST OFFICE ADDRESS			
C/ Soleracast, 118, 2 <sup>nd</sup> A, ES-08022-Barcelona, Spain			
FULL NAME OF EIGHTH JOINT INVENTOR, IF ANY		SIGNATURE	DATE
Ignacio Ruiz Serrano RESIDENCE			
C/ Ricardo Calvo, 8-10, 2 <sup>nd</sup> A, ES-08022-Barcelona, Spain			CITIZENSHIP Spain
POST OFFICE ADDRESS			
C/ Ricardo Calvo, 8-10, 2 <sup>nd</sup> A, ES-08022-Barcelona, Spain			

09647543.100200

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY (CONT'D) (Includes Reference to Provisional and PCT International Applications)	Attorney's Docket No.
	031309-003

FULL NAME OF NINTH JOINT INVENTOR, IF ANY	SIGNATURE	DATE
Rosa Elena Cardoza Silva		
RESIDENCE	CITIZENSHIP	
C/ José Bergamín, 5, 3 <sup>a</sup> C, ES-24195 Villacampo de las Requezas (I. HUN), Spain	Mexico	
POST OFFICE ADDRESS		
C/ José Bergamín, 5, 3 <sup>a</sup> C, ES-24195-Villacampo de las Requezas (LEON), Spain		

002001-64547960

9-0

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY (CONT'D) (Includes Reference to Provisional and PCT International Applications)		Attorney's Docket No. 031309-003
FULL NAME OF NINTH JOINT INVENTOR, IF ANY Rosa Elena Carillo Silva	SIGNATURE <i>[Signature]</i>	DATE September 29, 2000
RESIDENCE C/ José Bermúdez, S. 3 <sup>a</sup> C. 35-24193-Villanueva de las Regueras (LEÓN), Spain	CITIZENSHIP Mexico	ESX
POST OFFICE ADDRESS C/ José Bermúdez, S. 3 <sup>a</sup> C. 35-24193-Villanueva de las Regueras (LEÓN), Spain		

09647543.100200